Introduction {#s1}
============

White adipose tissue (WAT) represents the principle site for safe and efficient energy storage in mammals. WAT, as a whole, is considerably heterogeneous. WAT is composed of energy-storing adipocytes, various immune cell populations, vascular cells, adipocyte precursor cells (APCs), and largely uncharacterized stromal populations. The development and function of adipose tissue is highly dependent on critical interactions between adipocytes, APCs, immune cells, and endothelial cells ([@bib15]; [@bib20]).

WAT has a unique and remarkable capacity to expand and contract in size in response to changes in demand for energy storage. In the context of positive energy balance (nutrient excess), WAT expands to meet the increased demand for energy storage, leading ultimately to the condition of obesity. The manner by which WAT expands is a critical determinant of metabolic health in obesity. It has long been appreciated that individuals who preferentially accumulate WAT in subcutaneous regions are at a relatively lower risk for developing insulin resistance when compared to equally obese individuals with central (visceral) adiposity ([@bib26]; [@bib29]). It is now widely believed that visceral and subcutaneous WAT depots represent fundamentally distinct types of WAT ([@bib24]; [@bib32]; [@bib33]; [@bib52]). Indeed, visceral and subcutaneous WAT depots emanate from distinct developmental lineages ([@bib7]).

Importantly, another clear determinant of metabolic health in obesity is manner in which individual WAT depots expand and 'remodel' ([@bib17]; [@bib30]). WAT 'remodeling' associated with obesity can be described as both quantitative and qualitative changes in adipocyte numbers and stromal-vascular cell composition. Pathological WAT expansion is characterized by the presence of enlarged adipocytes, excessive macrophage accumulation, and fibrosis ([@bib11]; [@bib14]; [@bib16]; [@bib28]; [@bib45]). The prevailing hypothesis is that as 'overworked' fat cells reach their storage capacity, adipocyte death, inflammation, and fibrosis ensue ([@bib17]; [@bib44]). This is often associated with the deleterious accumulation of lipids in the liver, skeletal muscle, pancreas, and heart (termed 'lipotoxicity') ([@bib47]). Healthy WAT expansion occurs when adipose tissue expands through adipocyte hyperplasia (increase in adipocyte number through de novo differentiation) ([@bib10]; [@bib25]; [@bib27]). This is associated with a lower degree of chronic tissue inflammation and fibrosis. These adipose phenotypes of the 'metabolically healthy' obese tightly correlate with sustained insulin sensitivity in these patients. To date, the factors dictating a healthy vs. unhealthy WAT expansion in obesity remain poorly defined. In particular, the array of cell types within the adipose stromal-vascular compartment contributing to the remodeling of WAT in obesity has remained largely undefined.

The growing appreciation for the casual link between adipose tissue distribution and remodeling with systemic metabolic health has sparked considerable interest in defining the adipocyte precursors giving rise to fat cells in adults and the mechanisms controlling their differentiation in vivo ([@bib18]). In male C57BL/6 mice, adipose tissues expand in diet-induced obesity in a depot-selective manner. The epididymal WAT depot expands through both adipocyte hypertrophy and adipocyte hyperplasia ([@bib23]; [@bib25]; [@bib50]). The inguinal subcutaneous WAT depot expands almost exclusively by adipocyte hypertrophy. We recently reported that visceral adipocytes emerging in association with HFD feeding originate, at least in part, from perivascular precursors expressing *Pdgfrb* ([@bib48]). *Pdgfrb* encodes the platelet-derived growth factor receptor β chain (PDGFRβ protein) and is a widely used marker of perivascular cells ([@bib2]). We previously employed a pulse-chase lineage tracing mouse model to track the fate of *Pdgfrb*-expressing cells in adipose tissue. Following HFD feeding, *Pdgfrb*-expressing cells give rise to white adipocytes within visceral WAT depots ([@bib48]). The ability of these precursors to undergo de novo adipogenesis in the setting of diet-induced obesity is critical for healthy visceral WAT expansion ([@bib43]). Inducible genetic disruption of *Pparg*, the master regulatory gene of adipocyte differentiation, in *Pdgfrb*-expressing cells leads to a loss of de novo adipogenesis from *Pdgfrb*-expressing cells in the visceral WAT depot of diet-induced obese mice; this exacerbates the pathologic remodeling of this depot (i.e. increased inflammation and fibrosis). Driving de novo adipogenesis from *Pdgfrb*-expressing cells through transgenic *Pparg* expression leads to a healthy expansion of visceral WAT (lower inflammation and small adipocytes) ([@bib43]). The highly adipogenic subpopulation of PDGFRβ+ cells in gonadal WAT (gWAT) is quantitatively enriched in the expression of *Pparg*, as well as its upstream regulatory factor, *Zfp423* ([@bib12]; [@bib46]; [@bib48]). PDGFRβ+ cells enriched in these adipogenic factors express several mural cell (pericyte/smooth muscle) markers and reside directly adjacent to the endothelium in WAT blood vessels ([@bib12]; [@bib46]; [@bib48]). Using *Zfp423* reporter mice (*Zfp423*^GFP^ BAC transgenic mice), we revealed that PDGFRβ+ cells expressing high levels of *Zfp423* (GFP+ or *Zfp423*^High^) represent highly committed preadipocytes while *Zfp423*^Low^ cells (GFP-) lacked significant adipogenic capacity, and exhibited significantly different global patterns of gene expression ([@bib48]). These observations suggested that the pool of PDGFRβ+ cells in visceral WAT is functionally heterogeneous, with cells possessing distinct cellular phenotypes.

In this study, we set out to explore the functional heterogeneity within *Pdgfrb*-expressing cells of visceral WAT from adult mice. Furthermore, our objective was to identify improved strategies to purify adipocyte precursor populations from these depots. Through single-cell RNA-sequencing, we identified functionally distinct subpopulations of *Pdgfrb*-expressing progenitor cells. We identified a unique population of cells that display fibrogenic and functional pro-inflammatory phenotypes, and lack inherent adipogenic capacity. These fibro-inflammatory progenitors (termed here as 'FIPs') can be purified by the use of commercially available antibodies (LY6C + PDGFRβ+). On the other hand, LY6C- CD9- PDGFRβ+ cells represent a distinct pool of highly adipogenic visceral adipocyte precursor cells ('APCs') that robustly differentiate spontaneously in vitro in growth media containing insulin. The frequency of these PDGFRβ+ subpopulations is highly regulated under physiological conditions. These data reveal the functional heterogeneity of perivascular progenitors within visceral WAT and provide insight into how the adipose stroma can control WAT remodeling. Moreover, the molecular profiles obtained for FIPs and APCs from visceral WAT, along with the strategies to isolate these cells, will facilitate the study of physiological WAT remodeling in vivo.

Results {#s2}
=======

Single-cell RNA sequencing reveals molecularly distinct *Pdgfrb*-expressing subpopulations in visceral adipose tissue {#s2-1}
---------------------------------------------------------------------------------------------------------------------

We previously derived a doxycycline-inducible (Tet-On) lineage-tracing model that allows for the indelible labeling of *Pdgfrb*-expressing perivascular cells in adipose tissue of adult mice (*Pdgfrb*^rtTA^; *TRE-Cre; Rosa26R*^mT/mG^; herein, 'MuralChaser mice') ([@bib48]). Prior to exposing animals to doxycyline, all cells within the stromal-vascular fraction (SVF) of adult gonadal WAT (gWAT) express membrane tdTomato from the *Rosa26* locus. Following 9 days of exposure to doxycycline-containing chow diet, Cre-mediated excision of the *loxP*-flanked *tdTomato* cassette occurs in *Pdgfrb*-expressing cells, and membrane-bound GFP (mGFP) expression is constitutively activated ([Figure 1A](#fig1){ref-type="fig"}). As previously reported and confirmed here, FACS analysis indicated that nearly all mGFP+ cells are PDGFRβ+ as expected, and are devoid of CD45 (hematopoietic), CD31 (endothelial), and CD11b (monocyte/macrophage) expression ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}) ([@bib48]). Moreover, mGFP expression following transient doxycycline exposure is confined predominately to peri-endothelial cells in adult gonadal WAT ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}) ([@bib48]).

![Single-cell RNA sequencing reveals molecularly distinct *Pdgfrb*-expressing subpopulations in visceral adipose tissue.\
(**A**) Schematic overview of the MuralChaser model: a 'Tet-On' system allowing for indelible labeling of *Pdgfrb*-expressing cells. In the absence of doxycycline (Dox), gonadal SVF cells are labeled membrane tdTomato+ and are devoid of membrane GFP expression. In the presence of Dox, rtTA activates Cre expression in *Pdgfrb*-expressing cells. Cre excises the loxP-flanked membrane tdTomato (mtdTomato) cassette and allows constitutive activation of membrane GFP (mGFP) reporter expression. The gating strategy shows prospective isolation of tdTomato- GFP+ cells from the stromal vascular fraction of gonadal WAT (gWAT). (**B**) t-distributed stochastic neighbor embedding (*tSNE*) plot of 1045 tdTomato- GFP+ cells isolated from pooled gWAT depots from five male MuralChaser mice. Equal numbers of cells were combined from five individual mice for single-cell RNA-sequencing. Clustering was generated using *k*-means = 4. See [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}. (**C**) Distribution of *Gfp* and *tdTomato* expression within *tSNE* plot. Transcript counts represent Log~2~ of gene expression. (**D**) Heatmap of top 20 most differentially expressed genes defining the clusters indicated in (**B**). See [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}. (**E**) Gene expression distribution of adipocyte/adipogenesis-associated genes. (**F**) Gene expression distribution of genes associated with terminal adipocyte differentiation. (**G**) Gene expression distribution of genes associated with fibrosis and inflammation. (**H**) Gene expression distribution of mesothelial cell markers.\
10.7554/eLife.39636.006Figure 1---source data 1.Complete list of differentially expressed genes (k-means = 4).](elife-39636-fig1){#fig1}

We set out to test the hypothesis that *Pdgfrb*-expressing perivascular cells in gonadal visceral WAT of adult mice are heterogeneous, with subpopulations harboring functionally distinct phenotypes. To this end, we performed single cell RNA-sequencing (scRNA-seq) of mGFP+ cells isolated from gWAT of lean (chow fed) 8 week-old male MuralChaser mice following 9 days of doxycycline exposure. *t*SNE analysis of 1045 cell transcriptomes revealed distinct cell clusters exhibiting unique transcriptional profiles ([Figure 1B,C](#fig1){ref-type="fig"}). Many of the top 20 most enriched transcripts in Cluster 1A and Cluster 1B correspond to notable genes related to adipogenesis and/or adipocyte gene expression ([Figure 1D](#fig1){ref-type="fig"}). In particular, the majority of cells in Clusters 1A and 1B express high levels of *Pparg*, *Fabp4*, *Hsd11b1*, and *Lpl*, indicating these clusters may represent the PDGFRβ+ APC population within visceral WAT ([Figure 1E](#fig1){ref-type="fig"}). Interestingly, Cluster 1B further enriches in the expression of *Pparg*, *Cebpa*, and other markers of terminal adipocyte differentiation, including *Plin1*, *Fabp5*, *Car3*, and *Cd36* ([Figure 1F](#fig1){ref-type="fig"}). Notably, the expression of *Adipoq*, *Retn*, and *Adrb3*, genes typically characteristic of mature adipocytes, were detected within some cells within Cluster 1B ([Figure 1F](#fig1){ref-type="fig"}). Unbiased gene set enrichment analysis (GSEA) revealed that cells of Cluster 1A/B enriched for gene sets related to 'adipogenesis' and cells of Cluster 1B enriched for gene signatures of 'oxidative phosphorylation,' 'adipogenesis,' and fatty acid metabolism ([Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}). These data suggest Cluster 1A and 1B represent 'adipocyte precursor cells' (APCs), with Cluster 1B representing a subpopulation of APCs that are 'committed preadipocytes'.

10.7554/eLife.39636.007

###### Gene sets enriched in APCs (Cluster 1A/B).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene set name            Gene set\                      FDR q-value   Enriched genes
                           description                                  
  ------------------------ ------------------------------ ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HALLMARK_XENOBIOTIC\_\   Genes encoding proteins\       0.008879008   APOE, IGF1, NDRG2, VTN, HSD11B1, ENPEP, POR, TNFRSF1A, SLC1A5, JUP, PMM1, CD36, PTGES, FAH, FMO1, HMOX1, GCNT2, ABCD2, ECH1, GSTA3, AOX1, IL1R1, GABARAPL1, ID2, CASP6, CSAD, MPP2, DDT, GSTO1, ALDH2, TMEM176B, GSTT2, CYP27A1, CYB5A, SMOX, FBLN1, MCCC2, ELOVL5, NQO1, PDK4, ALAS1, ATP2A2, RBP4, TMEM97
  METABOLISM               involved in processing\                      
                           of drugs and other\                          
                           xenobiotics.                                 

  HALLMARK\_\              Genes up-regulated during\     0.033845212   GPX3, SPARCL1, COL15A1, APOE, LPL, COL4A1, MYLK, CMBL, LIFR, SDPR, EPHX2, PPARG, POR, MRAP, REEP6, SLC1A5, ENPP2, ANGPTL4, CD302, FABP4, ANGPT1, GPHN, CD36, SLC27A1, RAB34, LIPE, PTGER3, IFNGR1, FAH, ALDOA, SULT1A1, FZD4, SCP2, TST, ECH1, SLC19A1, ADCY6, TANK, CS, ACADM, DDT, UBC, MCCC1, ALDH2, BCKDHA, AGPAT3, DBT, JAGN1, MGST3, ADIPOR2, SLC5A6, DNAJC15, GPAM, PIM3, CYP4B1, RETSAT, ITGA7, SLC25A10, SCARB1
  ADIPOGENESIS             adipocyte differentiation\                   
                           (adipogenesis).                              

  HALLMARK_IL6_JAK\_\      Genes up-regulated by\         0.08689988    SOCS3, JUN, CNTFR, TNFRSF1A, CD38, PIM1, OSMR, CD36, IFNGR1, SOCS1, IL17RA, MYD88, HMOX1, IRF1, STAT3, IL1R1, STAT2
  STAT3_SIGNALING          IL6 via STAT3, e.g., during\                 
                           acute phase response.                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### Gene sets enriched in committed preadipocytes (Cluster 1B).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene set name           Gene set\                               FDR q-value   Enriched genes
                          description                                           
  ----------------------- --------------------------------------- ------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HALLMARK_MYC\_\         A subgroup of genes\                    0             SRM, GNL3, NOLC1, HSPE1, NIP7, HSPD1, PA2G4, NPM1, CDK4, PPAN, MYBBP1A, RCL1, PUS1, PHB, WDR43, HK2, WDR74, SLC19A1, GRWD1, EXOSC5, PES1, PRMT3, DDX18, TMEM97, IMP4, UNG, UTP20, LAS1L, MPHOSPH10, PPRC1, NOC4L, TBRG4, BYSL, IPO4, TFB2M
  TARGETS_V2              regulated by MYC - version 2.                         

  HALLMARK_OXIDATIVE\_\   Genes encoding proteins\                0             ATP5G1, NNT, COX8A, TIMM13, TIMM10, LDHA, CYCS, TOMM70A, UQCRQ, COX7C, CYC1, COX7A2, ATP5G2, TIMM50, ATP5E, NDUFA4, NDUFAB1, SLC25A5, ATP5L, SLC25A4, PHB2, ACAT1, ATP5J, ATP5C1, CS, NDUFB8, NDUFB2, GRPEL1, UQCRFS1, IDH3A, NDUFV2, COX5A, NDUFC2, MRPS15, NDUFB4, POR, ECHS1, ATP5B, MRPS12, COX7B, LDHB, COX4I1, ATP5D, MRPL15, COX6B1, UQCRH, MDH2, SLC25A3, TIMM9, ATP5G3, NDUFB5, PRDX3, NDUFA2, ATP5A1, MRPS30, ATP5H, NDUFA7, NDUFC1, COX5B, PDHB, ATP5F1, MAOB, BAX, NDUFA3, GPX4, NDUFS8, VDAC2, COX6C, POLR2F, NDUFS3, COX6A1, NDUFS2, UQCRB, TIMM17A, ACADM, NDUFS7, ATP5O, MRPL11, IDH1, MRPL35, SUCLG1, HCCS, SDHD, MRPL34, MRPS11, NDUFB7, VDAC1, ATP5J2, NDUFA8, GOT2, OXA1L, SLC25A11, NDUFS6, NDUFA6, ETFB, IMMT, HTRA2, MTRR, FXN, SDHB, ACO2, FDX1, NDUFB6, DLAT, PMPCA, DLD, IDH2, AFG3L2, ETFDH, MTX2, TIMM8B, RETSAT, COX7A2L, TOMM22, NDUFA5, SUCLA2, UQCRC1, ALDH6A1, RHOT1, ECH1, SURF1, ATP6V1G1, VDAC3, PDHX, LRPPRC, UQCRC2, HADHB
  PHOSPHORYLATION         involved in oxidative\                                
                          phosphorylation.                                      

  HALLMARK\_\             Genes up-regulated\                     0             REEP6, COL15A1, MYLK, APOE, COX8A, PIM3, CMBL, UQCRQ, LPL, SLC1A5, CYC1, PPARG, NDUFAB1, TKT, YWHAG, CS, DBT, GRPEL1, IDH3A, SCP2, SLC25A10, POR, ECHS1, FZD4, G3BP2, COX7B, SLC19A1, AK2, MRPL15, JAGN1, ENPP2, MDH2, ALDOA, PRDX3, MRAP, RAB34, DDT, MTCH2, HADH, PTGER3, LIPE, CPT2, REEP5, MCCC1, ANGPT1, GPX4, AGPAT3, NDUFS3, COX6A1, TANK, ACADM, SCARB1, ATP5O, ADCY6, GPX3, IDH1, SUCLG1, PEX14, SPARCL1, SDPR, PREB, GHITM, ALDH2, ADIPOR2, NDUFB7, EPHX2, ACADS, DNAJC15, GPHN, HIBCH, FAM73B, CHUK, VEGFB, ETFB, IMMT, ACOX1, RREB1, QDPR, FABP4, ACLY, ELOVL6, SDHB, PFKL, ACO2, RETN, CAT, PTCD3, DLAT, DLD, TST, CD36, DHRS7B, ITSN1, RETSAT, NDUFA5, UQCRC1, UBQLN1, DNAJB9, ECH1, SLC27A1
  ADIPOGENESIS            during adipocyte\                                     
                          differentiation (adipogenesis).                       

  HALLMARK_MYC\_\         A subgroup of genes\                    0             RPLP0, SRM, RPL6, GNL3, RPS2, RPL18, CNBP, RPS5, APEX1, RPL14, RPS6, RANBP1, SERBP1, ERH, C1QBP, RPL34, NOLC1, HSPE1, GNB2L1, HSPD1, PABPC1, SET, LDHA, EIF4A1, RPS3, PA2G4, SNRPD1, RSL1D1, TOMM70A, RAN, DDX21, NPM1, EIF2S2, CYC1, PABPC4, CDK4, IMPDH2, FBL, NAP1L1, NDUFAB1, RPL22, ABCE1, PHB2, HDGF, SNRPD2, LSM7, RPS10, HSP90AB1, PHB, CCT2, PPM1G, SNRPD3, SYNCRIP, PCBP1, CCT3, LSM2, EPRS, NME1, EIF2S1, GSPT1, COX5A, CCT7, CCT5, TUFM, U2AF1, PPIA, TCP1, ODC1, POLE3, ACP1, EEF1B2, TARDBP, YWHAE, SLC25A3, EIF1AX, SNRPA1, ETF1, SRPK1, PSMD7, PRDX3, SMARCC1, RAD23B, CCT4, RNPS1, FAM120A, RUVBL2, TXNL4A, EIF4E, KARS, PTGES3, GLO1, DDX18, MCM7, HDAC2, CANX, DUT, PRPF31, UBE2L3, KPNB1, NCBP1, SNRPA, POLD2, PSMA7, EIF4G2, PSMB2, PRPS2, DHX15, SSBP1, CLNS1A, PSMB3, PGK1, XPOT, STARD7, H2AFZ, ILF2, VDAC1, SSB, CTPS, GOT2, MRPS18B, SNRPG, COPS5, MRPL9, PSMA2, CAD, PSMA4, TRIM28, IARS, SF3B3, PSMD14, SNRPB2, UBE2E1, NCBP2, PWP1, YWHAQ, PSMD8, AP3S1, RFC4, HDDC2, PSMA6, XPO1, VDAC3, PSMC4, CDK2, USP1, MYC, PCNA, MRPL23
  TARGETS_V1              regulated by\                                         
                          MYC - version 1 (v1).                                 

  HALLMARK\_\             Genes involved\                         0.001391793   AK1, TMED2, BOLA2, IMPDH2, POLR1D, SAC3D1, APRT, NUDT9, NME1, NUDT21, SSRP1, RAE1, ADRM1, GTF2A2, GUK1, POLR2D, GTF2H5, GPX4, POLR2F, MPG, DUT, SEC61A1, ADCY6, POLR2E, POLE4, RBX1, NT5C3, POLR1C, AK3, POLR2C, TAF10, GTF2H1, RNMT, DDB1, NME4, NFX1, POLR3GL, EIF1B, POLR2G, NCBP2, POLR2K, POLR2H, SURF1, ERCC8, TSG101, RFC4, RFC5, PCNA, UPF3B, POLR2I, RAD51, ITPA, EDF1, PRIM1, DAD1, TAF12, GTF2F1, POLD3, TCEB3, DCTN4, ARL6IP1, POLA1
  DNA_REPAIR              in DNA repair.                                        

  HALLMARK\_\             Genes up-regulated through\             0.001159828   PSAT1, ATP5G1, HSPE1, HSPD1, LDHA, TOMM40, SLC1A5, EIF2S2, ENO1, EEF1E1, PHGDH, ARPC5L, SQLE, EPRS, HSPA4, PPIA, PSME3, HK2, GAPDH, MTHFD2, ETF1, ALDOA, PDAP1, PPA1, XBP1, ABCF2, BCAT1, UBE2D3, CACYBP, CYB5B, PSMA3, SLC7A5, TXNRD1, CANX, INSIG1, TMEM97, IDH1, HMBS, SSR1, PSMB5, ADIPOR2, PGK1, SERPINH1, UNG, PLOD2, PSPH, PRDX1, POLR3G, RPN1, DAPP1, IMMT, SLC2A1, QDPR, ACLY, ELOVL6, ATP2A2, PFKL, GTF2H1, COPS5, LDLR, SHMT2, UFM1, PSMA4, FDXR, TCEA1, GMPS, IDI1, PSMD12, ELOVL5, PSMD14, MAP2K3, PITPNB, MLLT11, TPI1, GSK3B, M6PR, PSMC4, ME1, NUP205, SLC2A3, NUFIP1, GSR, UCHL5, HMGCR
  MTORC1_SIGNALING        activation of mTORC1 complex.                         

  HALLMARK_FATTY\_\       Genes encoding proteins\                0.00329518    REEP6, MIF, APEX1, LDHA, AOC3, FASN, SUCLG2, ECHS1, ODC1, MDH2, ALDOA, HADH, PDHB, BCKDHB, CPT2, ACADM, SETD8, ADSL, IDH1, SUCLG1, HCCS, SDHD, ADIPOR2, ERP29, H2AFZ, ACADS, HIBCH, PRDX6, ACOX1, GSTZ1, ACO2, GRHPR, G0S2, DLD, CD36, ACSL1, IDI1, ELOVL5, ETFDH, CCDC58, RETSAT, METAP1, SUCLA2, ECH1, HSP90AA1, HSPH1, MCEE, HADHB, ME1, GCDH, IDH3B, CRAT, SDHC, MLYCD, AQP7, DLST, HSD17B7, HMGCS1, SMS, GPD1, RDH11, ACADVL, NSDHL, HMGCL, DECR1, ACSL5, UROS
  ACID_METABOLISM         involved in metabolism\                               
                          of fatty acids.                                       

  HALLMARK\_\             Genes annotated by the\                 0.002883282   CNBP, PABPC1, SLC25A4, SCP2, SMARCC1, PEX11A, FDPS, SLC35B2, SOD2, IDH1, PEX14, EPHX2, CTPS, GNPAT, PRDX1, PEX13, NUDT19, ACOX1, CTBP1, CAT, IDH2, ACSL1, IDI1, ELOVL5, RETSAT, ECH1, ABCD3, SLC25A17, PEX5, CDK7, CRAT, MLYCD, PEX11B, HRAS, DHRS3, ISOC1, RDH11, ABCD2, HMGCL, ACSL5, SLC23A2, SOD1, TOP2A, CRABP1
  PEROXISOME              GO term GO:0005777. A small,\                         
                          membrane-bounded organelle\                           
                          that uses dioxygen (O2) to\                           
                          oxidize organic molecules;\                           
                          contains some enzymes that\                           
                          produce and others that degrade\                      
                          hydrogen peroxide (H2O2).                             

  HALLMARK\_\             Genes encoding cell cycle related\      0.004273379   RANBP1, NOLC1, CKS1B, PA2G4, RAN, LYAR, CDK4, NAP1L1, SYNCRIP, NME1, EIF2S1, GSPT1, PHF5A, MTHFD2, AK2, NUDT21, SSRP1, SNRPB, TIPIN, UBE2S, IPO7, PNN, MCM7, SHMT1, DUT, H2AFX, NUP153, HN1, POLD2, POLE4, HMGB3, H2AFZ, UNG, CTPS, HELLS, PAICS, CENPM, ILF3, RBBP7, PSIP1, RAD1, TBRG4, NASP, PRPS1, PSMC3IP, TK1, BRMS1L, RAD51AP1, CDKN2A, CTCF, RAD50, POP7, XPO1, TCF19, ASF1A, CDKN2C, USP1, NUP205, MYC, PCNA, POLE, PPP1R8, ASF1B, SMC1A, ATAD2, DIAPH3, MCM5, CCNB2, DEK, RFC1, XRCC6, BRCA2, CSE1L, EZH2, ANP32E, POLD3, MCM2, SMC6, MCM6, RQCD1, DONSON, ZW10, CKS2, BRCA1, MRE11A, RPA3, KIF22, PLK4, BIRC5, CDC25A, GINS1, CDCA3, KPNA2, HMMR, SMC4, CCNE1, MXD3, EXOSC8, RFC2, MLH1, TRIP13, TOP2A, MAD2L1
  E2F_TARGETS             targets of E2F transcription factors.                 

  HALLMARK\_\             Genes up-regulated during\              0.005032035   PSAT1, RPS14, NOLC1, CKS1B, EIF4A1, EEF2, NPM1, DKC1, LSM4, EIF4EBP1, EIF2S1, EXOSC1, MTHFD2, SDAD1, XBP1, EXOSC5, EIF4E, EIF4G1, SLC7A5, EXOSC2, H2AFX, CEBPG, SSR1, PREB, XPOT, BANF1, DDX10, EXOSC4, FUS, PARN, TARS, LSM1, SRPRB, IARS, SPCS1, DNAJB9, BAG3, EIF4A2
  UNFOLDED\_\             unfolded protein response, a\                         
  PROTEIN_RESPONSE        cellular stress response related\                     
                          to the endoplasmic reticulum.                         

  HALLMARK_G2M\_\         Genes involved in the G2/M\             0.005412505   NCL, NOLC1, CKS1B, SNRPD1, CDK4, DKC1, DTYMK, UCK2, SYNCRIP, SQLE, GSPT1, HSPA8, ODC1, EWSR1, SMARCC1, RAD23B, HMGN2, UBE2S, PRPF4B, DR1, PRMT5, AMD1, SLC7A5, SETD8, H2AFX, HN1, KPNB1, HMGB3, SFPQ, H2AFZ, ILF3, TNPO2, SLC7A1, TOP1, NASP, CBX1, NUP50, CASP8AP2, E2F4, CTCF, XPO1, CDKN2C, MYC, CUL4A, POLE, CCNT1, YTHDC1, SMC1A, MCM5, CCNB2, BRCA2, CASC5, KATNA1, POLQ, EZH2, CUL1, MCM2, ODF2, MTF2, MCM6, WHSC1, NEK2, E2F1, SMC2, SS18, CKS2, E2F3, KIF22, PLK4, HIF1A, EXO1, BIRC5, H2AFV, CDC25A, KPNA2, CHAF1A, PAFAH1B1, HMMR, SMC4, PBK, TROAP, GINS2, CENPF, CCNA2, RBM14, TOP2A, MAD2L1, KIF11, STMN1, BUB3, DBF4, RPA2, TPX2, RBL1, BARD1, UPF1, CENPE, ATRX, KIF5B, HIRA, PRC1, CCND1, CDC27, CHEK1, CENPA, SUV39H1, MNAT1, STIL, POLA2, TFDP1, FBXO5, PURA, MKI67, AURKA, UBE2C, EGF, CDC25B, ZAK, TMPO, CUL5, MCM3, WRN, MYBL2, RAD54L, LIG3, TTK, SMAD3, RACGAP1
  CHECKPOINT              checkpoint, as in progression\                        
                          through the cell division cycle.                      

  HALLMARK_REACTIVE\_\    Genes up-regulated by\                  0.011108679   MGST1, NDUFB4, SOD2, GPX4, TXNRD1, NDUFS2, GPX3, PRDX2, PRDX6, PRDX1, NDUFA6, PPP2R4, CAT, MSRA, GLRX2
  OXIGEN_SPECIES\_\       reactive oxigen species (ROS).                        
  PATHWAY                                                                       

  HALLMARK_PI3K\_\        Genes up-regulated by\                  0.012494773   PLA2G12A, PTEN, CDK4, PRKAR2A, PPP1CA, PFN1, PIN1, UBE2D3, EIF4E, PLCB1, UBE2N, AKT1S1, AKT1, RPS6KA3, TNFRSF1A, DAPP1, SLC2A1, YWHAB, PPP2R1B, MKNK2, CFL1, ECSIT, MAPKAP1, MAP2K3, PLCG1, ATF1, GSK3B, RAF1, CDK2, MAP3K7, ARHGDIA, HRAS, CAB39L, RIPK1, E2F1, CALR, AP2M1, MYD88, CSNK2B, ARF1, PTPN11, PAK4, SMAD2
  AKT_MTOR\_\             activation of the\                                    
  SIGNALING               PI3K/AKT/mTOR pathway.                                

  HALLMARK\_\             Genes encoding proteins\                0.018676866   IGF1, APOE, CSAD, SLC1A5, GSTO1, RBP4, PMM1, POR, ENPEP, ACP1, NDRG2, DDT, BCAT1, KARS, PTGES3, IL1R1, TMEM97, IDH1, PTGES, ALDH2, MCCC2, TNFRSF1A, ACOX1, MTHFD1, ATP2A2, TPST1, PGD, ACO2, CAT, SHMT2, IGFBP4, GART, CD36, ELOVL5, ETFDH, RETSAT, SSR3, ADH5, DDAH2, ECH1
  XENOBIOTIC\_\           involved in processing of\                            
  METABOLISM              drugs and other xenobiotics.                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The cells in Cluster 2 were highly enriched in the expression of genes associated with fibrosis and inflammation, including *Fn1*, *Loxl2*, *Tgfb2*, and *Ccl2* ([Figure 1D and G](#fig1){ref-type="fig"}). GSEA revealed the enrichment of numerous gene signatures characteristic of a fibrogenic and inflammatory phenotype, including gene sets corresponding to 'inflammatory response,' 'TGFβ signaling,' 'TNFα signaling,' and 'hypoxia' ([Table 3](#table3){ref-type="table"}). This fibro-inflammatory molecular signature of *Pdgfrb*-expressing cells suggested this subpopulation represents 'fibro-inflammatory progenitors' (herein, termed 'FIPs').

10.7554/eLife.39636.009

###### Gene sets enriched in FIPs.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene set name            Gene set\                                                                                                                                                                                                                                                                                                FDR q-value   Enriched genes
                           description                                                                                                                                                                                                                                                                                                            
  ------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HALLMARK_PANCREAS\_\     Genes specifically up-regulated\                                                                                                                                                                                                                                                                         0             DPP4, LMO2, SRP9, SRP14
  BETA_CELLS               in pancreatic beta cells.                                                                                                                                                                                                                                                                                              

  HALLMARK\_\              Genes annotated by the GO term GO:0006954. The immediate defensive reaction to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.   5.02E-04      AXL, CD55, HAS2, ITGB3, EMP3, IRF7, TNFRSF1B, NFKBIA, EDN1, DCBLD2, ATP2B1, CCL2, SRI, IL18, BST2, ADORA2B, CSF1, TNFAIP6, ADM, ITGA5, CCL7, TLR2, TPBG, HIF1A, PDPN, TAPBP, ABI1, KLF6, NFKB1, SERPINE1, GNAI3, RHOG, CCRL2, SLC7A1, ABCA1, SLC4A4, CDKN1A, GPC3, PVR, PLAUR, IFNGR2, IL18R1, RELA, IL6, P2RY2, EIF2AK2, TIMP1, MMP14, GCH1, LIF, CXCL10, KIF1B
  INFLAMMATORY\_\                                                                                                                                                                                                                                                                                                                                 
  RESPONSE                                                                                                                                                                                                                                                                                                                                        

  HALLMARK_UV\_\           Genes down-regulated in response to ultraviolet (UV) radiation.                                                                                                                                                                                                                                          0.00149668    TGFBR2, EFEMP1, CYR61, FYN, CDON, HAS2, LAMC1, ANXA4, ITGB3, MGLL, ANXA2, PMP22, COL1A1, APBB2, ATP2B1, VLDLR, SRI, NR3C1, FBLN5, ADORA2B, COL1A2, COL3A1, PDLIM5, FZD2, IGFBP5, DUSP1, ADD3, SMAD7, SYNE1, CITED2, TGFBR3, NOTCH2, NFKB1, SERPINE1, ATRX, SDC2, SLC7A1, IGF1R, VAV2, CDKN1B, NEK7
  RESPONSE_DN                                                                                                                                                                                                                                                                                                                                     

  HALLMARK\_\              Genes encoding components of blood coagulation system; also up-regulated in platelets.                                                                                                                                                                                                                   0.00112251    FN1, FBN1, PRSS23, DPP4, S100A13, FYN, BMP1, ANXA1, ITGB3, GDA, SPARC, CD9, PLAT, RAC1, ARF4, WDR1, CAPN2, ADAM9, SERPINE1, PECAM1, MAFF, DUSP14, KLF7, GNB2, HMGCS2, GNG12, TIMP1, TIMP3, MMP14
  COAGULATION                                                                                                                                                                                                                                                                                                                                     

  HALLMARK_TGF\_\          Genes up-regulated in response to TGFB1.                                                                                                                                                                                                                                                                 8.98E-04      RHOA, SPTBN1, FKBP1A, BMP2, SKIL, SMURF2, CTNNB1, SMURF1, CDKN1C, SKI, SMAD7, BMPR2, SERPINE1, TGFBR1, ID3, IFNGR2, SMAD1, ACVR1, KLF10
  BETA_SIGNALING                                                                                                                                                                                                                                                                                                                                  

  HALLMARK_EPITHELIAL\_\   Genes defining epithelial-mesenchymal transition, as in wound healing, fibrosis and metastasis.                                                                                                                                                                                                          7.48E-04      FN1, PCOLCE2, MFAP5, FBN1, FSTL1, LOXL1, CYR61, BMP1, THY1, LAMC1, ITGB3, EMP3, ECM1, SFRP4, DPYSL3, LOXL2, TPM4, SPARC, CAPG, CALU, LGALS1, PMP22, BASP1, TNFRSF11B, COL1A1, ITGB5, POSTN, FGF2, ANPEP, FLNA, PRRX1, CXCL1, EFEMP2, THBS2, TPM1, ITGAV, PPIB, TNFRSF12A, PDLIM4, SAT1, FBLN5, COL1A2, PTHLH, DST, LAMC2, COL3A1, IGFBP4, TPM2, ITGA5, COL16A1, ITGB1, WIPF1, FBN2, CALD1, PFN2, FZD8, TGFBR3, NOTCH2, SERPINE1, COL12A1
  MESENCHYMAL_TRANSITION                                                                                                                                                                                                                                                                                                                          

  HALLMARK_APICAL\_\       Genes encoding components of apical junction complex.                                                                                                                                                                                                                                                    7.89E-04      FBN1, CD34, ACTG1, ADRA1B, THBS3, BMP1, THY1, MYH10, SIRPA, ZYX, CNN2, FLNC, TNFRSF11B, ARPC2, YWHAH, EPB41L2, LIMA1, MSN, ITGA9, PFN1, ACTB, VCL, PVRL3, RSU1, LAMC2, PARVA, COL16A1, ITGB1, PVRL1, CTNNA1, ADAM9, ADAM15, GAMT, PECAM1, PVRL4, CD276, VAV2, RRAS
  JUNCTION                                                                                                                                                                                                                                                                                                                                        

  HALLMARK_ALLOGRAFT\_\    Genes up-regulated during transplant rejection.                                                                                                                                                                                                                                                          9.30E-04      CD47, THY1, RPL39, TGFB2, IRF7, CAPG, RPS9, FLNA, B2M, RPS19, CCL2, RPL9, CSK, GALNT1, IL18, CSF1, CCND3, INHBB, CCL7, TLR2, HIF1A, TAPBP, ELF4, IRF4, ABI1, PSMB10, CD80, IFNGR2, IL6, NPM1, UBE2D1, TIMP1
  REJECTION                                                                                                                                                                                                                                                                                                                                       

  HALLMARK_APICAL\_\       Genes encoding proteins over-represented on the apical surface of epithelial cells, e.g., important for cell polarity (apical area).                                                                                                                                                                     0.002962323   SULF2, THY1, HSPB1, DCBLD2, EFNA5, ADAM10, PLAUR, ATP8B1
  SURFACE                                                                                                                                                                                                                                                                                                                                         

  HALLMARK_MITOTIC\_\      Genes important for mitotic spindle assembly.                                                                                                                                                                                                                                                            0.002666091   MARCKS, FLNB, MYH10, TRIO, SPTBN1, FLNA, EPB41L2, SPTAN1, MAPRE1, RALBP1, CAPZB, ARHGAP29, ABL1, VCL, NIN, DST, ARF6, PDLIM5, CLASP1, YWHAE, KIFAP3, PXN, LMNB1, ARHGDIA, ABI1, NOTCH2, BIN1, DOCK4, KIF5B, PKD2, MYO1E, HOOK3, FARP1, WASF2, DYNC1H1, PREX1, MYH9, CKAP5, SMC3, SOS1, ITSN1, DYNLL2, CDK5RAP2, SMC1A, ARHGEF3, ESPL1, KIF1B, NEDD9, TIAM1, PPP4R2, ROCK1, PALLD, CD2AP, WASF1, CDC42BPA, RASA2, CDC42EP2, RHOT2, ALMS1, APC, PCM1, CDC27
  SPINDLE                                                                                                                                                                                                                                                                                                                                         

  HALLMARK\_\              Genes encoding components of the complement system, which is part of the innate immune system.                                                                                                                                                                                                           0.003505879   FN1, DPP4, CD55, TIMP2, ATOX1, S100A13, GNGT2, FYN, KIF2A, IRF7, PLA2G4A, PLAT, CXCL1, CALM1, EHD1, PFN1, ADAM9, IRF2, SERPINE1, GNAI3, RHOG, PRCP, MAFF, GCA, DOCK4, PLAUR, GNB2, IL6, CEBPB, TIMP1, GNAI2, XPNPEP1, MMP14
  COMPLEMENT                                                                                                                                                                                                                                                                                                                                      

  HALLMARK_PROTEIN\_\      Genes involved in protein secretion pathway.                                                                                                                                                                                                                                                             0.004820185   GNAS, PAM, ATP1A1, CLTA, ADAM10, DST, AP2B1, VAMP3, SSPN, RPS6KA3, MAPK1, SCRN1, AP3S1, ARFGAP3, SOD1, ABCA1, AP2S1, COPE, SNX2, ARFIP1, AP2M1, ARCN1, COPB1, ANP32E, LMAN1, CLTC, ERGIC3, DNM1L, RAB22A, TMED10, KIF1B, BET1, RAB14, COPB2, TSG101, AP3B1, STX12, GOLGA4, VPS4B, ARF1, MON2, RER1
  SECRETION                                                                                                                                                                                                                                                                                                                                       

  HALLMARK_TNFA\_\         Genes regulated by NF-kB in response to TNF.                                                                                                                                                                                                                                                             0.008500786   GFPT2, NR4A1, MARCKS, CYR61, PTGS2, SPSB1, NFKBIA, NR4A3, NFE2L2, EDN1, FOSL2, KLF2, CXCL1, ATP2B1, EIF1, PLK2, CCL2, B4GALT5, BMP2, EHD1, CCNL1, IER3, IL18, SAT1, NFIL3, CSF1, TNFAIP6, PDLIM5, NR4A2, TLR2, DUSP1, TRIP10, JAG1, RELB, PER1, IER2, TUBB2A, IER5, CXCL2, KLF6, NFKB1, SERPINE1, CCRL2, NFKBIE, MAFF, ABCA1, CDKN1A, KLF4, PLAUR, CD80, NFKB2, IFNGR2, RELA, IL6, CEBPB, GEM, FOSL1, IFIT2, DNAJB4, KLF10, ETS2, DDX58, GCH1, LIF
  SIGNALING_VIA_NFKB                                                                                                                                                                                                                                                                                                                              

  HALLMARK_HYPOXIA         Genes up-regulated in response to low oxygen levels (hypoxia).                                                                                                                                                                                                                                           0.01474173    PRDX5, CYR61, AKAP12, EXT1, CSRP2, PLAC8, UGP2, NDRG1, PTRF, ANXA2, PRKCDBP, PAM, HAS1, FOSL2, VLDLR, SLC6A6, HS3ST1, NAGK, ERRFI1, NR3C1, IER3, NFIL3, ADORA2B, ADM, CDKN1C, DUSP1, TPBG, DTNA, TPST2, CITED2, HK1, WSB1, KLF6, SERPINE1, GAPDH, SDC2, MAFF, AMPD3, PFKP, CDKN1A, CTGF, GPC3, IDS, PLAUR, KLF7, CDKN1B, PGM1, IL6, SULT2B1, TES, XPNPEP1, MYH9, HK2
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cluster 3 was molecularly quite distinct from Clusters 1A/B and 2. Interestingly, Cluster 3 had a mesothelial-like cell (herein, 'MLCs') expression profile. Mesothelial cells are epithelial cells of mesodermal origin that form a monolayer (mesothelium) lining the visceral serosa. Mesothelial cells and mural cells share a common developmental lineage. Multiple genetic lineage tracing studies in mice indicate that various stromal cell populations within visceral tissues, including APCs, descend from embryonic mesothelial cells ([@bib7]; [@bib37]). Mesothelial cells have been linked to multiple aspects of adipose tissue development and remodeling, including adipogenesis and inflammation ([@bib9]; [@bib13]; [@bib35]). Cluster 3 was enriched for genes representing common mesothelial/epithelial markers, such as *Msln*, *Upk3b*, *Krt8*, and *Krt14* ([Figure 1D and H](#fig1){ref-type="fig"}). The presence of this cluster suggested that the *Pdgfrb*^rtTA^ transgene targets at least a subset of visceral WAT associated mesothelial cells. Indeed, following transient doxycycline treatment of MuralChaser mice, a few mGFP+ cells can be observed within in the outermost epithelial layer of gonadal WAT ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Moreover, mGFP+ cells can be occasionally observed within cultures of isolated mesothelial cells obtained from gWAT of doxycycline-treated MuralChaser mice ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}).

We performed a second scRNA-seq analysis utilizing independently isolated mGFP+ cells from gonadal WAT MuralChaser mice ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). From the second scRNA-seq dataset, we again identified the same major subpopulations of *Pdgfrb*-expressing cells. All together, these scRNA-seq data reveal molecularly distinct *Pdgfrb*-expressing subpopulations in visceral adipose tissue.

Molecularly distinct visceral WAT PDGFRβ+ subpopulations can be isolated by FACS {#s2-2}
--------------------------------------------------------------------------------

Next, we developed a strategy to isolate these molecularly distinct cell populations by flow cytometry from wild type mice. For this purpose, we treated Cluster 1A and 1B as one broad 'APC' population ([Figure 2A](#fig2){ref-type="fig"}). Candidate cell surface markers were selected on the basis of their corresponding gene expression in the three PDGFRβ+ subpopulations and the availability of commercial antibodies suitable for FACS. Of note, *Ly6c1* expression was abundant in FIPs but not APCs ([Figure 2B](#fig2){ref-type="fig"}). The expression of *Cd9*, a recently described marker of fibrogenic cells ([@bib34]), was abundantly expressed in both the FIPs and MLCs ([Figure 2B](#fig2){ref-type="fig"}). Therefore, we isolated the three populations based on these markers using fluorescence-activated cell sorting. PDGFRβ+ cells (CD31- and CD45-) were subdivided on the basis of LY6C and CD9 immunoreactivity ([Figure 2B,C](#fig2){ref-type="fig"}). Three distinct subpopulations of PDGFRβ+ cells were apparent: LY6C- CD9- (APCs), LY6C+ (FIPs), and LY6C- CD9+ (MLCs) cells ([Figure 2C](#fig2){ref-type="fig"}). Flow cytometry analysis consistently revealed that LY6C+ PDGFRβ+ cells were more abundant than LY6C- CD9- PDGFRβ+ cells and Ly6C- CD9+ PDGFRβ+ cells ([Figure 2D](#fig2){ref-type="fig"}). Importantly, gene expression analysis by qPCR revealed that LY6C- CD9- PDGFRβ+ cells were enriched in the expression of genes that defined the APC population (Cluster 1) ([Figure 2E,F](#fig2){ref-type="fig"}). LY6C+ PDGFRβ+ cells enriched for the mRNAs that initially defined the FIPs (Cluster 2) ([Figure 2E,G](#fig2){ref-type="fig"}), and LY6C- CD9+ PDGFRβ+ cells expressed the mesothelial/epithelial markers that defined Cluster 3 ([Figure 2E,H](#fig2){ref-type="fig"}). Collectively, these data provide independent validation of the scRNA-seq data of genetically labeled *Pdgfrb*-expressing cells, and establish a method for isolating PDGFRβ+ subpopulations from gWAT of adult wild type mice using commercially available antibodies.

![Isolation of gonadal WAT PDGFRβ+ subpopulations by FACS.\
(**A**) *tSNE* plot of cells from [Figure 1B](#fig1){ref-type="fig"} with k-means = 3 clustering. See [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}. (**B**) Distribution of *Ly6c1* and *Cd9* expression within *tSNE* plot. Transcript counts represent Log~2~ of gene expression. (**C**) Fluorescence-activated cell sorting (FACS) gating strategy to isolate indicated PDGFRβ+ CD31 CD45- subpopulations from gWAT. (**D**) Frequency of APCs, FIPs, and MLCs in gonadal WAT isolated from lean male 8 week old C57BL/6 mice. Frequencies were quantified based on the gating strategy shown in (**C**). n = 6. (**E**) Heatmap of top 20 most differentially expressed genes that define the clusters depicted in (**A**). See [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}. (**F**) mRNA levels of Cluster 1 genes in freshly isolated APCs (LY6C- CD9-), FIPs (LY6C+), and MLCs (LY6C- CD9-), obtained from gWAT of lean male 8 week old C57BL/6 mice. n = 4. (**G**) mRNA levels of Cluster 2 genes in same sorted populations shown in (**F**). n = 4. (**H**) mRNA levels of Cluster 3 genes in same sorted populations shown in (**F**). n = 4. \* in all graphs denote p\<0.05 by student's t-test in comparisons to the other populations. Bars represent mean +SEM.\
10.7554/eLife.39636.011Figure 2---source data 1.Complete list of differentially expressed genes (k-means = 3).](elife-39636-fig2){#fig2}

LY6C- CD9- PDGFRβ+ cells are functional visceral white adipocyte precursors {#s2-3}
---------------------------------------------------------------------------

The global molecular signature of LY6C- CD9- PDGFRβ+ cells (Cluster 1) suggests this population represents APCs. Indeed, freshly sorted LY6C- CD9- PDGFRβ+ cells are enriched in *Pparg* expression when compared to LY6C+ PDGFRβ+ cells ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). We explored this hypothesis by testing the ability of these subpopulations to undergo adipocyte differentiation in vitro. We isolated and cultured all three subpopulations in growth medium containing 2% FBS and 1% ITS (insulin, transferrin, selenium). These represent culture conditions that we previously established for growth and differentiation of gWAT-derived PDGFRβ+ cells ([@bib48]). Under these growth conditions, LY6C+ PDGFRβ+ cells proliferate at a greater rate than LY6C- CD9- PDGFRβ+ cells; however, the two subpopulations appear morphologically indistinguishable, with both populations appearing fibroblast-like until reaching confluence ([Figure 3---figure supplement 1B,C,E](#fig3s1){ref-type="fig"}). LY6C- CD9+ PDGFRβ+ cells (MLCs) grow to confluence and adopt a cobblestone-like morphology characteristic of cultured mesothelial cells ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). Remarkably, upon reaching confluence, only LY6C- CD9- PDGFRβ+ cells (APCs) underwent spontaneous adipocyte differentiation at a high efficiency, while very few adipocytes emerged in the other two PDGFRβ+ subpopulations or within cultures containing all PDGFRβ+ cells from gWAT ([Figure 3](#fig3){ref-type="fig"}). FIPs appeared to possess some latent capacity to undergo adipogenesis. Confluent cultures of LY6C+ PDGFRβ+ cells stimulated with a more commonly used hormonal adipogenic cocktail (dexamethasone, IBMX, insulin, and PPARγ agonist, Rosiglitazone) underwent to adipocyte differentiation to some degree ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Despite this strong adipogenic stimulus, LY6C+ PDGFRβ+ cells still did not differentiate to the same extent as LY6C- CD9- PDGFRβ+ cells stimulated with insulin alone (see [Figure 3](#fig3){ref-type="fig"}). We also assessed the ability of APCs and FIPs to undergo adipocyte differentiation in vivo. We transplanted 80,000 cells into the remnant subcutaneous WAT depots of *Adipoq*-Cre; *Pparg*^loxP/loxP^ animals, a well-described model of lipodystrophy ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}) ([@bib49]). 3 weeks following cell transplantation, the WAT depots all four animals injected with LY6C- CD9- PDGFRβ+ cells contain numerous clusters of lipid-laden fat cells ([Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}). The contralateral depots of the same animals injected with LY6C+ PDGFRβ+ cells, or matrigel alone, remained devoid of adipocytes ([Figure 3---figure supplement 3C,D](#fig3s3){ref-type="fig"}). Collectively, these data indicate that LY6C- CD9- PDGFRβ+ cells are highly adipogenic functional gonadal white adipocyte precursors, while LY6C+ PDGFRβ+ cells are largely refractory to adipogenic stimuli.

![LY6C- CD9- PDGFRβ+ cells (APCs) are functional gonadal white adipocyte precursors.\
(**A**) Photograph of Oil Red O (ORO) stained gWAT-derived PDGFRβ+ cells maintained for 8 days in growth media (2% FBS and ITS supplement). (**B**) Photograph of ORO stained LY6C- CD9- PDGFRβ+ cells maintained for 8 days in growth media. (**C**) Photograph of ORO stained LY6C+ PDGFRβ+ cells maintained for 8 days in growth media. (**D**) Photograph of ORO stained LY6C- CD9+ PDGFRβ+ cells maintained for 8 days in growth media. (**E**) Brightfield image of the culture shown in A. Scale bar = 400 μm. (**F**) Brightfield image of the culture shown in B. Scale bar = 400 μm. (**G**) Brightfield image of the culture shown in C. Scale bar = 400 μm. (**H**) Brightfield image of the culture shown in D. Scale bar = 400 μm. (**I**) Brightfield image of the culture shown in A. Scale bar = 200 μm. (**J**) Brightfield image of the culture shown in B. Scale bar = 200 μm. (**K**) Brightfield image of the culture shown in C. Scale bar = 200 μm. (**L**) Brightfield image of the culture shown in D. Scale bar = 200 μm. (**M**) Brightfield image of unstained PDGFRβ+ cells maintained for 8 days in growth media. Scale bar = 100 μm. (**N**) Brightfield image of unstained LY6C- CD9- PDGFRβ+ cells maintained for 8 days in growth media. Scale bar = 100 μm. (**O**) Brightfield image of unstained LY6C+ PDGFRβ+ cells maintained for 8 days in growth media. Scale bar = 100 μm. (**P**) Brightfield image of unstained LY6C- CD9+ PDGFRβ+ cells maintained for 8 days in growth media. Scale bar = 100 μm. (**Q**) mRNA levels of adipocyte-selective genes in total PDGFRβ+ cells, APCs, FIPs, and MLCs, after 8 days of culture in growth media. \* denotes p\<0.05 by student's t-test in comparisons to total PDGFRβ+ cells. Bars represent mean +SEM. n = 4--7. All photographs/images are representative of multiple experiments/repetitions (See [Supplementary file 1](#supp1){ref-type="supplementary-material"}).](elife-39636-fig3){#fig3}

Several studies have defined APCs from gonadal WAT as SCA-1+ CD34+ CD24± cells that also express PDGFRα ([@bib3]; [@bib23]; [@bib31]; [@bib38]). In fact, most studies of gonadal WAT APCs isolate these cells on the basis of these markers. Additionally, recent studies identified CD38 as a marker of committed preadipocytes ([@bib5]). The scRNA-seq analysis and follow-up qPCR analyses of isolated subpopulations revealed that all three PDGFRβ+ subpopulations indeed expressed *Pdgfra*, *Ly6a* (SCA-1), and *Cd34*; however, the mRNA levels of *Ly6a* and *Cd34* are actually lower in LY6C- CD9- PDGFRβ+ APCs than in LY6C+ PDGFRβ+ cells (FIPs) ([Figure 3---figure supplement 1F,G](#fig3s1){ref-type="fig"}). As expected, all three subpopulations expressed *Pdgfrb*; however, mRNA levels of *Pdgfrb* were quantitatively lower in FIPs than in the APCs and MLCs. qPCR analysis indicated that levels of *Cd24a* were low in all three PDGFRβ+ subpopulations. *Cd38* was present predominately in LY6C- CD9- PDGFRβ+ cells, consistent with the notion that CD38 identifies APCs from this depot ([@bib5]) ([Figure 3---figure supplement 1F,G](#fig3s1){ref-type="fig"}). Flow cytometry analyses revealed similar patterns of surface protein expression in these subpopulations ([Figure 3---figure supplement 1H](#fig3s1){ref-type="fig"}). Collectively, these data reveal the selection of gonadal WAT SVF cells on the basis of SCA-1/CD34 yields functionally heterogeneous cell populations, and perhaps biases against the selection of LY6C- CD9- PDGFRβ+ APCs.

Recently, Burl et al. reported scRNA-seq profiles of adipose SVF cells, creating a cellular atlas of potential adipocyte precursor populations (perivascular and non-perivascular) ([@bib4]). Notably, the authors identified two prominent populations within the gonadal WAT depot, termed adipose stem cell (ASC) 1 and ASC 2. Moreover, they identified two additional smaller ASC subpopulations that were considered 'differentiating' ASCs and 'proliferating' ASCs. The identified populations were not isolated and explored functionally in their study; however, a comparison of the molecular profiles strongly suggests that ASC 1 defined by the authors bears close resemblance to APC population defined in our study, while the ASC 2 population bears close resemblance to the FIPs discovered here ([Figure 3---figure supplement 1I](#fig3s1){ref-type="fig"}). Markers of the differentiated/proliferative ASCs aligned closely to the committed PDGFRβ+ preadipocyte depicted in [Figure 1B](#fig1){ref-type="fig"}. Taken together, our data here suggest a refined strategy to isolate functional white adipocyte precursors from visceral WAT of adult mice.

Our prior studies of *Zfp423*^GFP^ reporter mice indicated that gonadal WAT PDGFRβ+ cells expressing GFP are enriched in the expression of *Pparg* and are highly adipogenic in vitro ([@bib12]; [@bib48]). Additional studies by others indicated that this reporter captures committed preadipocytes within the skeletal bone marrow microenvironment ([@bib1]). Endogenous *Zfp423* mRNA levels were found in all PDGFRβ+ subpopulations, albeit at highest levels in APCs. ([Figure 3---figure supplement 4A](#fig3s4){ref-type="fig"}). We re-examined *Zfp423*^GFP-High^ and *Zfp423*^GFP-Low^ PDGFRβ+ cells isolated from gWAT ([Figure 3---figure supplement 4B](#fig3s4){ref-type="fig"}), asking whether these labeled cells captured by this reporter allele enriched for any of the Cluster markers identified by scRNA-seq. Consistent with our prior studies, *Zfp423*^GFP-High^ PDGFRβ+ cells were enriched in the expression of *Pparg* isoforms when compared to *Zfp423*^GFP-Low^ PDGFRβ+ cells ([Figure 3---figure supplement 4C](#fig3s4){ref-type="fig"}). Further gene expression analysis of the top cluster gene markers revealed that *Zfp423*^GFP-High^ cells were enriched in the expression of the genes that define the APC clusters, but not FIPs or MLCs ([Figure 3---figure supplement 4D--G](#fig3s4){ref-type="fig"}). In particular, *Zfp423*^GFP-High^ PDGFRβ+ cells were enriched in the expression of genes that delineate the more committed preadipocytes cluster (Cluster 1B) identified by scRNA-seq ([Figure 3---figure supplement 4E](#fig3s4){ref-type="fig"}). Taken all together, these data indicate that endogenous *Zfp423* mRNA expression is not confined exclusively to the APC subpopulation of PDGFRβ+ cells in gWAT; however, *Zfp423*^GFP^ reporter mice represent a genetic tool to localize and enrich for committed preadipocytes from this depot.

Functionally distinct stromal populations from visceral, but not subcutaneous, WAT depots can be revealed on the basis of LY6C and CD9 expression {#s2-4}
-------------------------------------------------------------------------------------------------------------------------------------------------

Transcriptional programs of white adipocyte precursors are depot- and sex dependent ([@bib33]). Thus, we asked whether similar functional heterogeneity exists amongst PDGFRβ+ cells within various WAT depots, and whether functionally distinct subpopulations could be selected for using the same FACS strategy described above. Indeed, the same three populations can be observed within the mesenteric and retroperitoneal depots of adult male mice, with LY6C- CD9- PDGFRβ+ cells representing the highly adipogenic subpopulation ([Figure 4A--H](#fig4){ref-type="fig"}). We also examined LY6C expression within PDGFRβ+ SVF cells obtained from the inguinal and anterior subcutaneous WAT depots. We previously demonstrated that the total pool of PDGFRβ+ cells from inguinal WAT is very highly adipogenic in vitro ([@bib43]); however, remarkably, all PDGFRβ+ cells within the inguinal and anterior subcutaneous WAT depots expressed LY6C ([Figure 4I](#fig4){ref-type="fig"}). These data suggest that if heterogeneity exists amongst PDGFRβ+ cells in these subcutaneous depots, subpopulations could not be discriminated on the basis of LY6C expression. Therefore, functionally distinct perivascular cell subpopulations from visceral, but not subcutaneous, WAT depots can be revealed on the basis of LY6C and CD9 expression.

![Functionally distinct stromal populations from visceral, but not subcutaneous, WAT depots can be revealed on the basis of LY6C and CD9 expression.\
(**A**) Fluorescence-activated cell sorting (FACS) gating strategy to isolate indicated PDGFRβ+ CD31- CD45- subpopulations from mesenteric and retroperitoneal WAT. (**B**) Frequency of APCs, FIPs, and MLCs in mesenteric and retroperitoneal WAT isolated from lean male 8 week old C57BL/6 mice. Frequencies were quantified based on the gating strategy shown in (**A**). n = 6. Bars represent mean +SEM. (**C**) Brightfield image of LY6C- CD9- PDGFRβ+ (APCs) cells from mesenteric WAT maintained for 8 days in growth media. Scale bar = 200 μm. (**D**) Brightfield image of LY6C+ PDGFRβ+ (FIPs) cells from mesenteric WAT maintained for 8 days in growth media. Scale bar = 200 μm. (**E**) Brightfield image of LY6C- CD9+ PDGFRβ+ (MLCs) cells from mesenteric WAT maintained for 8 days in growth media. Scale bar = 200 μm. (**F**) Brightfield image of LY6C- CD9- PDGFRβ+ (APCs) cells from retroperitoneal WAT maintained for 8 days in growth media. Scale bar = 200 μm. (**G**) Brightfield image of LY6C+ PDGFRβ+ (FIPs) cells from retroperitoneal WAT maintained for 8 days in growth media. Scale bar = 200 μm. (**H**) Brightfield image of LY6C- CD9+ PDGFRβ+ (MLCs) cells from retroperitoneal WAT maintained for 8 days in growth media. Scale bar = 200 μm. (**I**) Flow cytometry plot of LY6C and CD9 expression in CD31- CD45- PDGFRβ+ cells isolated from inguinal WAT and anterior subcutaneous WAT.](elife-39636-fig4){#fig4}

We also asked whether visceral WAT in female mice contains APCs and FIPs, bearing similar molecular and functional properties. Within the SVF of peri-ovarian WAT, the same three distinct subpopulations of PDGFRβ+ cells can be discriminated, with FIPs being the predominant population ([Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). Importantly, gene expression analysis by qPCR confirmed that LY6C- CD9- PDGFRβ+ cells were enriched in the expression of genes that defined the epididymal WAT APC population (Cluster 1) ([Figure 4---figure supplement 1C,F](#fig4s1){ref-type="fig"}), including *Pparg* isoform 2. LY6C+ PDGFRβ+ cells enriched for the mRNAs that initially defined the epididymal WAT FIPs (Cluster 2) ([Figure 4---figure supplement 1D,G,H](#fig4s1){ref-type="fig"}), and LY6C- CD9+ PDGFRβ+ cells expressed mesothelial/epithelial markers ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). Moreover, LY6C- CD9- PDGFRβ+ cells from peri-ovarian WAT are functional adipocyte precursors; these cells, but neither FIPs nor MLCs, differentiate spontaneously upon reaching confluence in culture ([Figure 4---figure supplement 1I--K](#fig4s1){ref-type="fig"}). Collectively, these data provide evidence that functional APCs from both male and female visceral WAT can be isolated through this cell sorting strategy.

Visceral LY6C+ PDGFRβ+ cells are anti-adipogenic and appear molecularly distinct from inguinal WAT Aregs {#s2-5}
--------------------------------------------------------------------------------------------------------

It is notable that very little spontaneous adipocyte differentiation occurs in cultures containing the total pool of visceral adipose PDGFRβ+ cells ([Figure 3A,E,I,M,Q](#fig3){ref-type="fig"}), despite the presence of numerous APCs within this population. This suggested that perhaps the presence of FIPs within these cultures influenced the differentiation capacity of neighboring APCs in vitro. Therefore, we also tested the impact of conditioned media from cultured FIPs on the differentiation capacity of APCs residing in parallel cultures. Remarkably, APCs exposed to conditioned media from FIPs, but not from parallel cultures of APCs, expressed lower levels of *Pparg* ([Figure 5A](#fig5){ref-type="fig"}). Moreover, APCs exposed to conditioned media from FIPs lost a significant degree of adipogenic capacity ([Figure 5B,C,E](#fig5){ref-type="fig"}). Conditioned media from cultures of MLCs had only a slight inhibitory effect on the terminal differentiation of APCs ([Figure 5D,E](#fig5){ref-type="fig"}). Collectively, these data not only suggest that FIPs lack significant adipogenic capacity, but highlight the notion that these cells can actually be anti-adipogenic.

![FIPs inhibit adipocyte differentiation from APCs.\
(**A**) *Pparg* isoform two expression in cultured APCs maintained for 3 days in conditioned media from either APCs, FIPs, or MLCs. n = 4. \*denotes p\<0.05 by student's t-test in comparisons to data represented in blue bars. Bars represent mean +SEM. (**B**) Brightfield image of APCs after 8 days of culture in conditioned media from parallel cultures of APCs. Scale bar = 100 μm for B-D. (**C**) Brightfield image of APCs after 8 days of culture in conditioned media from parallel cultures of FIPs. (**D**) Brightfield image of APCs after 8 days of culture in conditioned media from parallel cultures of MLCs. (**E**) mRNA levels of adipocyte-selective genes within cultures shown in (**B--D**). n = 3. \* denotes p\<0.05 by student's t-test in comparisons to data represented in blue bars. Bars represent mean +SEM. (**F**) Distribution of *Abcg1* and *F3* expression within *tSNE* plot from [Figure 1B](#fig1){ref-type="fig"}. (**G**) mRNA levels of *Abcg1* and *F3* in APCs, FIPs, and MLCs isolated from lean 8 week old male mice. \* denotes p\<0.05 by student's t-test. Bars represent mean +SEM. (**H**) tSNE-plot highlighting the potential relationship between APCs, FIPs, and MLCs, and iguinal WAT Aregs identified by Schwalie et al. ([@bib40]). The top-23 Areg-selective genes identified by Schwalie et al were input into Cell Loupe Browser. Color intensities represent the sum of the Log~2~ expression values of the Areg selective gene list within the single cell RNA-sequencing dataset of gWAT from [Figure 1B](#fig1){ref-type="fig"}.](elife-39636-fig5){#fig5}

Recently, Schwalie et al. identified anti-adipogenic stromal cells within the inguinal WAT of mice ([@bib40]). These cells, termed Aregs, are defined, in part, by the expression of CD142 and ABCG1 and exhibit perivascular localization. From our scRNA-seq dataset, we observed that *F3* expression (encoding CD142) is detected in all PDGFRβ+ clusters of gonadal WAT, albeit not enriched in FIPs ([Figure 5F](#fig5){ref-type="fig"}). *Abcg1* expression was not detected by the sequencing analysis in any population. We also examined the levels of mRNA for these two markers directly by quantitative PCR analysis. Consistent with the sequencing data, neither marker was enriched in FIPs ([Figure 5G](#fig5){ref-type="fig"}). We also examined additional genes (23 in total) whose expression defines Aregs, as identified by Schwalie et al, by assessing their expression level within our scRNA-seq dataset ([Figure 5H](#fig5){ref-type="fig"}). Levels of transcripts corresponding to a number of these genes were detectable, albeit at low levels. Notably, there was no selective enrichment of the broader set of Areg markers within FIPs or APCs. As such, despite some shared functional similarities, inguinal adipose Aregs and the gonadal adipose FIPs described here appear molecularly distinct.

Visceral LY6C+ PDGFRβ+ cells are fibrogenic and exert a functional pro-inflammatory phenotype {#s2-6}
---------------------------------------------------------------------------------------------

As described above, GSEA of scRNA-seq profiles also identified a gene expression profile suggestive of active TGFβ signaling within Cluster 2 cells ([Table 3](#table3){ref-type="table"}). Indeed the expression of major collagens (*Col1a1* and *Col3a1*) and some of the assayed genes associated with extracellular matrix accumulation were enriched in freshly isolated LY6C+ PDGFRβ+ cells compared to the other PDGFRβ+ subpopulations ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). In vitro, cultured FIPs and APCs were both responsive to treatment with recombinant TGFβ; however, the expression of collagens examined remained higher and/or was further induced in FIPs ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). These data indicate that LY6C+ PDGFRβ+ FIPs exhibit a phenotype characteristic of fibrogenic cells.

The most striking result from GSEA was the enrichment of pathways related to active 'Tnfα signaling' and 'inflammatory response' in FIPs ([Table 3](#table3){ref-type="table"}). Remarkably, FIPs exhibited a robust inflammatory gene expression signature following acute exposure to pro-inflammatory molecules. Lipopolysaccharide (LPS) treatment induced inflammatory cytokine gene expression in both APCs and FIPs; however, the response was more robust in the latter population ([Figure 6A](#fig6){ref-type="fig"}). The differential response to TNFα treatment was the most striking; FIPs, but not APCs, activate the expression of several pro-inflammatory cytokines under these conditions ([Figure 6B](#fig6){ref-type="fig"}). These fibro-inflammatory cells displayed increased gene expression of numerous cytokines involved in the recruitment of leukocytes and the activation of immune cells. This suggested that FIPs have the potential to activate macrophages through cytokine production. To test this, we treated cultured bone marrow derived macrophages with conditioned media from LPS-treated FIPs, APCs, and MLCs ([Figure 6C](#fig6){ref-type="fig"}). Macrophage cultures exposed to conditioned media from LPS-treated FIPs had the most robust induction of pro-inflammatory genes, including *Tnfα*, *Il1β*, and *Il6* ([Figure 6D](#fig6){ref-type="fig"}). These data highlight the potential for FIPs to exert a functional pro-inflammatory phenotype.

![LY6C+ PDGFRβ+ cells (FIPs) exhibit a functional pro-inflammatory phenotype.\
(**A**) mRNA levels of indicated cytokines in cultures of APCs and FIPs treated with vehicle (PBS) or LPS (100 ng/ml) for 3 hr. \* denotes p\<0.05 by student's t-test. Bars represent mean +SEM. n = 4. (**B**) mRNA levels of indicated cytokines in cultures of APCs and FIPs treated with vehicle (PBS) or TNFα (20 ng/ml) for 3 hr. \* denotes p\<0.05 by student's t-test. Bars represent mean +SEM. n = 4. (**C**) Schematic depicting the treatment of bone marrow derived macrophages (MΦ) with conditioned media (CM) from LPS-treated APCs, FIPs and MLCs. (**D**) mRNA levels of select markers of activated macrophages in macrophage cultures exposed to conditioned media. n = 4. \* denotes p\<0.05 comparing vehicle vs. LPS. \# denotes p\<0.05 comparing LPS-treated FIPs vs. LPS-treated APCs. Bars represent mean +SEM.](elife-39636-fig6){#fig6}

The frequencies and gene expression profiles of APCs and FIPs are differentially regulated in association with high-fat diet feeding {#s2-7}
------------------------------------------------------------------------------------------------------------------------------------

In the setting of caloric excess, adipose tissue undergoes a dramatic remodeling as it expands to meet increased demands for energy storage. Shortly after the onset of high-fat diet (HFD) feeding, adipose tissue inflammation occurs ([@bib19]; [@bib51]). After 4--5 weeks of HFD feeding (60% kcal from fat), newly formed visceral adipocytes emerging from the PDGFRβ+ lineage begin to appear ([@bib48]). We asked if the frequency of FIPs and APCs were altered during the course of HFD feeding. Four weeks of HFD feeding did not appear to dramatically alter the absolute number of PDGFRβ+ cells present in gWAT; however, the ratio of FIPs to APCs begins to increase by as early as one week of HFD feeding ([Figure 7A](#fig7){ref-type="fig"}). We also analyzed BrdU incorporation into the mural cell populations during one week of HFD feeding. FIPs and the MLCs displayed the greatest BrdU incorporation ([Figure 7B,C](#fig7){ref-type="fig"}). BrdU incorporation into APCs was significantly lower than observed in the FIPs ([Figure 7B,C](#fig7){ref-type="fig"}). These data indicate that frequencies of APCs and FIPs are differentially regulated in vivo in association with high-fat diet feeding, with FIPs exhibiting a relatively higher degree of cell proliferation under these conditions.

![The frequencies and gene expression profiles of APCs and FIPs are differentially regulated in association with high-fat diet feeding.\
(**A**) Frequency of total PDGFRβ+ cells, FIPs, and APCs in gonadal WAT isolated from chow-fed mice, mice fed high fat diet (HFD) for 1 week, or mice fed HFD for 4 weeks. n = 4. \* denotes p\<0.05 by student's t-test in comparison to white bars. \# denotes p\<0.05 by student's t-test in comparison to red or white bars. Bars represent mean +SEM. (**B**) Histograms depicting BrdU incorporation into APCs, FIPs, and MLCs after 1 week of chow or HFD feeding. (**C**) Relative median fluorescence intensity (MFI) corresponding to histograms shown in (**B**). n = 4. \* denotes p\<0.05 by student's t-test in comparison to corresponding data from APCs. \# denotes p\<0.05 by student's t-test in comparison to corresponding data from APCs and MLCs. (**D**) *Pparg* isoform two expression in freshly isolated APCs, FIPs, and MLCs, from gWAT of chow or 4 week HFD fed mice. n = 4. (**E**) *Il6* expression in same cell populations shown in (**D**). (**F**) *Ccl2* expression in same cell populations shown in (**D**). (**G**) *Cxcl2* expression in same cell populations shown in (**D**). (**H**) *Tnfa* expression in same cell populations shown in (**D**). (**I**) *Tgfb1* expression in same cell populations shown in (**D**). (**J**) *Tgfb2* expression in same cell populations shown in (**D**). (**K**) *Fn1* expression in same cell populations shown in (**D**). (**L**) *Col1a1* expression in same cell populations shown in (**D**). (**M**) *Col3a1* expression in same cell populations shown in (**D**). \* in panels D-M denote p\<0.05 by student's t-test. All bars represent mean +SEM.](elife-39636-fig7){#fig7}

The change in frequency of FIPs and APCs during HFD feeding prompted us to examine if their defining gene expression programs were altered under these conditions. One month of HFD feeding lead to a significant elevation in mRNA levels of *Pparg* isoform two expression in APCs, with a smaller increase occurring in MLCs ([Figure 7D](#fig7){ref-type="fig"}). *Pparg* isoform two expression was not elevated in FIPs, consistent with their apparent lack of adipogenic potential ([Figure 7D](#fig7){ref-type="fig"}). mRNA levels of pro-inflammatory cytokines and extracellular matrix components were further induced and/or remained more abundant in FIPs than in APCs or MLCs ([Figure 7E--M](#fig7){ref-type="fig"}). Interestingly, APCs activated the expression of some of these genes (e.g. *Il6*, *Tnfa*, *Col1a1*, *Col3a1*) during HFD feeding. These data are consistent with the in vitro analyses highlighting the potential of APCs to trigger some degree of an inflammatory response in pro-inflammatory stimuli (see [Figure 6](#fig6){ref-type="fig"}). These data reveal that PDGFRβ+ subpopulations exhibit unique transcriptional responses to HFD feeding; however, these data also suggest that APCs have some capacity to adopt characteristics of FIPs in vivo.

NR4A nuclear receptors regulate the pro-inflammatory phenotype of PDGFRβ+ cells {#s2-8}
-------------------------------------------------------------------------------

We sought to gain insight into the potential transcriptional mechanisms regulating the pro-inflammatory and adipogenic phenotypes of PDGFRβ+ perivascular cells. A number of transcription factors were differentially expressed between FIPs and APCs; however, it was notable that the expression of all three members of the *Nr4a* family of nuclear hormone receptors was significantly enriched in the FIPs cluster ([Figure 8A](#fig8){ref-type="fig"}). Gene expression analysis by qPCR of the isolated populations confirmed the significant enrichment of *Nr4a1*, *Nr4a2*, and *Nr4a3* in FIPs isolated from chow-fed mice, with relatively lower expression in the APCs and MLCs ([Figure 8B](#fig8){ref-type="fig"}).

![NR4A nuclear receptors regulate the pro-inflammatory phenotype of PDGFRβ+ cells.\
(**A**) Distribution of *Nr4a1, Nr4a2, and Nr4a3* expression, within *tSNE* plot depicted in [Figure 1B](#fig1){ref-type="fig"}. Transcript counts represent Log~2~ of gene expression. (**B**) *Nr4a* mRNA levels in freshly isolated APCs, FIPs, and MLCs, isolated from the gonadal WAT of lean chow-fed male mice. n = 4. (**C**) *Nr4a* mRNA levels in freshly isolated APCs, FIPs, and MLCs, isolated from the gonadal WAT of male mice following 4 weeks of high-fat diet (HFD) feeding. n = 4. (**D**) Relative mRNA levels of *Nr4a* family members in cultures of FIPs treated with vehicle (PBS) or TNFα (20 ng/ml) for 3 hr. n = 4. \* denotes p\<0.05 by student's t-test. n = 4. (**E**) Relative mRNA levels of *Nr4a1* in FIPs 3 days following transduction with retrovirus expressing either *Gfp* or *Nr4a1*. n = 4. (**F**) Relative mRNA levels of *Nr4a2* in FIPs 3 days following transduction with retrovirus expressing either *Gfp* or *Nr4a2*. n = 4. (**G**) Relative mRNA levels of *Nr4a3* in FIPs 3 days following transduction with retrovirus expressing either *Gfp* or *Nr4a3*. n = 4. (**H**) *Cxcl2* expression in FIPs 3 days following transduction with indicated retroviruses and treated with vehicle (PBS) or TNFα (20 ng/ml) for 4 hr. n = 4. (**I**) *Cxcl10* expression in same cultures shown in (**H**). (**J**) *Ccl2* expression in same cultures shown in (**H**). (**K**) *Il6* expression in same cultures shown in (**H**). (**L**) Relative mRNA levels of *Nr4a1* in FIPs following transduction with retrovirus expressing shRNA targeting *Gfp* (shGFP) (control) or retroviruses individually expressing distinct shRNAs targeting unique regions of *Nr4a1* mRNA (shNr4a1 \#1--3). n = 4. (**M**) *Ccl2* expression in FIPs following transduction with indicated retroviruses and treatment with vehicle (PBS) or TNFα (20 ng/ml) for 3 hr. n = 4. (**N**) *Tnfa* expression in same cultures shown in (**C**). (**O**) *Cxcl2* expression in same cultures shown in (**C**). (**P**) *Il6* expression in same cultures shown in (**C**). \* in panels E-P denote p\<0.05 by student's t-test in comparison to corresponding treatments of control cells (pMSCV-GFP or shGFP). Bars in all graphs represent mean +SEM.](elife-39636-fig8){#fig8}

Members of the NR4A family, including NR4A1 (NUR77), NR4A2 (NURR1), and NR4A3 (NOR1), have been implicated in the regulation of inflammation; however, their exact impact on inflammatory signaling appears cell-type specific ([@bib39]). Following 4 weeks of HFD-feeding, the expression of *Nr4a* family members remained significantly enriched in FIPs ([Figure 8C](#fig8){ref-type="fig"}). In vitro, the expression of all *Nr4a* family members in FIPs was increased following exposure to recombinant TNFα ([Figure 8D](#fig8){ref-type="fig"}). Therefore, we assessed the consequences of retroviral-mediated overexpression of individual *Nr4a* family members on the inflammatory response of FIPs ([Figure 8E--G](#fig8){ref-type="fig"}). Overexpression of *Nr4a1*, *Nr4a2*, or *Nr4a3*, attenuated the pro-inflammatory response to TNFα ([Figure 8H--K](#fig8){ref-type="fig"}). Moreover, we assessed the impact of retroviral-mediated knockdown of *Nr4a1* on the inflammatory response in FIPs. Knockdown of *Nr4a1* using three independent shRNAs led to an exaggerated response of FIPs to TNFα treatment ([Figure 8L--P](#fig8){ref-type="fig"}). These gain- and loss of function studies suggest that FIPs activate *Nr4a* family members in response to pro-inflammatory stimuli, perhaps as a means to counter-regulate a sustained cellular inflammatory response. These data provide proof of concept that FIPs may be utilized as a tool to identify additional regulators of inflammatory signaling pathways.

Discussion {#s3}
==========

Visceral adipose tissue dysfunction in obesity is driven, at least in part, by chronic tissue inflammation, collagen deposition, and a loss of adipocyte precursor activity. WAT remodeling involves substantial qualitative and quantitative changes to the composition of the stromal compartment of the tissue; however, the functional heterogeneity of WAT stromal-vascular fraction has remained poorly defined and tools to isolate and study distinct subpopulations have been lacking. Here, we unveil functionally distinct PDGFRβ+ stromal cell subpopulations in visceral WAT ([Figure 9](#fig9){ref-type="fig"}). Importantly, we have developed strategies to prospectively isolate these distinct populations using commercially available antibodies.

![Functional heterogeneity of PDGFRβ+ perivascular cells in visceral adipose tissue of mice.\
The pool of PDGFRβ+ cells in visceral WAT of mice is molecularly and functionally heterogeneous. LY6C- CD9- PDGFRβ+ cells represent visceral adipocyte precursor cells (APCs), whereas LY6C+ PDGFRβ+ cells represent fibro-inflammatory progenitors (FIPs). FIPs are fibrogenic, pro-inflammatory, and inhibit adipocyte differentiation from APCs.](elife-39636-fig9){#fig9}

Functional analyses indicate that a relatively large subpopulation of PDGFRβ+ perivascular cells in visceral gonadal WAT exert fibrogenic and pro-inflammatory phenotypes. These cells, termed here as 'FIPs,' lack adipogenic capacity in vitro but instead exhibit a fibrogenic phenotype. FIPs are physiologically regulated; the frequency of these cells increases upon HFD feeding. Clement and colleagues previously reported that fibrogenic cells residing in WAT could be identified by the expression of CD9 and PDGFRα ([@bib34]). Indeed, FIPs express CD9 and PDGFRα; however, both CD9 and PDGFRα are also expressed in at least a subpopulation of mesothelial cells isolated from visceral WAT. As such, the selection of FIPs on the basis of LY6c and PDGFRβ expression (LY6C+ PDGFRβ+) represents a strategy to prospectively and specifically isolate FIPs from mouse gonadal WAT. Importantly, our data reveal a number of previously unappreciated ways in which perivascular cells may impact WAT remodeling ([Figure 9](#fig9){ref-type="fig"}). The LY6C+ PDGFRβ+ cells described here have the capacity to inhibit adipocyte differentiation from APCs through the release of secreted factors. The presence of highly anti-adipogenic stromal cells within the total PDGFRβ+ population may explain the apparent lack of adipogenic capacity that crude/unpurified visceral PDGFRβ+ cultures possess vitro, despite the presence of APCs. It is notable that visceral adipose FIPs appear distinct from the recently identified Aregs of inguinal WAT. Stromal cell heterogeneity may be depot-specific, with different depots utilizing distinct cell types to control their function and plasticity. The exact identities of the secreted factors and mechanisms that mediate the anti-adipogenic activity of FIPs and Aregs are still unknown. Importantly, whether FIPs and Aregs act to suppress/restrain adipocyte hyperplasia under physiological settings in vivo needs to be further explored.

FIPs also exert a functional pro-inflammatory phenotype in response to pro-inflammatory stimuli. It is notable that the frequency of FIPs increases following the onset of HFD feeding. This raises an intriguing hypothesis for future studies that perivascular stromal cells can modulate local tissue inflammation. This notion is in line with recent studies indicating that vascular mural cells can serve as 'gatekeepers' of inflammation in the lung ([@bib22]). On the other hand, one may expect that the increased frequency of FIPs would also completely blunt the differentiation of APCs in this depot. This is clearly not the case as gonadal WAT in mice is able to expand through adipocyte hyperplasia in the setting of diet-induced obesity. One possibility is that the anti-adipogenic activity of FIPs (rather than the frequency per se) is diminished by local signals in an attempt to facilitate adipogenesis within the depot. Another possibility lies in the spatial distribution of activated FIPs and APCs; their proximity to one another may influence their activity. The identification of these populations from the MuralChaser mice essentially places them within the perivascular compartment of adipose tissue; however, where APCs and FIPs are localized and become activated within the tissue is still unknown. Clearly, additional studies of these cells will be needed in order to determine their precise contribution to WAT inflammation and health in various settings in vivo. Furthermore, it is certainly plausible that FIPs contribute to WAT remodeling beyond fibrosis, inflammation, and adipogenesis.

The ability to isolate functionally distinct subpopulations of mural cells affords the possibility of identifying factors regulating these diverse mural cell phenotypes. Our gene expression analysis revealed the enrichment in mRNA levels of *Nr4a* family members in FIPs. Several studies have implicated NR4A nuclear receptors as modulators of inflammatory signaling; the precise impact of NR4A members on inflammation appears context/cell type specific. In some studies, NR4A family members are observed as being pro-inflammatory ([@bib36]). In other settings, NR4A expression is induced in response to pro-inflammatory stimuli but acts as a molecular brake on inflammatory signaling. Our gain- and loss of function studies suggest that FIPs activate *Nr4a* family members in response to pro-inflammatory stimuli to serve as a transcriptional brake on inflammatory cytokine gene expression. This counter-regulatory response may be a mechanism to limit cellular oxidative stress and apoptosis driven by inflammatory signaling ([@bib39]). Chao et al. previously demonstrated that NR4A family members are potent regulators of adipocyte differentiation ([@bib6]). Thus, NR4A members may play multiple roles in controlling of the fate and function of adipose perivascular cells. Additional studies involving the genetic manipulation of *Nr4a* family members in PDGFRβ+ cells in vivo will be needed to elucidate the exact requirements of NR4A members in WAT remodeling in vivo. Importantly, the ability to isolate FIPs and APCs affords the possibility of employing several different types of genomic approaches in an effort to reveal novel molecular mechanisms controlling adipose tissue inflammation, fibrosis, and adipogenesis.

As described above, there has been tremendous interest in elucidating the identity of adipocyte precursors in adult adipose tissue. Pioneering studies from Friedman and colleagues led to a now widely-used strategy to prospectively isolate adipocyte progenitor cells from freshly isolated WAT ([@bib38]). APCs have been isolated on the basis of CD29, SCA-1, and CD34 expression (CD29+ CD34+ SCA-1+ CD31- CD45-). These markers have proven to be quite useful for the selection of APCs from inguinal WAT and other WAT depots; however, a notable observation made here is that SCA-1 expression is in fact enriched in FIPs rather than APCs of the gonadal WAT depot. As such, the selection of cells on the basis of SCA-1 expression from this particular WAT depot yields a functionally heterogeneous population that likely includes FIPs, and perhaps even enriches for these cells. This may explain, at least in part, the notable lack of adipogenic potential that isolated gonadal CD34+ SCA-1+ cells possess in vitro ([@bib8]). Our prior work pointed to *Zfp423* as a marker of committed preadipocytes; however, our scRNA-seq data reveal that *Zfp423* expression is not confined exclusively to the APC subpopulation of PDGFRβ+ cells; *Pdgfrb*-expressing MLCs and FIPs also express *Zfp423*. Nevertheless, the selection of GFP^High^ PDGFRβ+ cells from gWAT of *Zfp423*^GFP^ reporter mice enriches for committed APCs, perhaps reflecting increased promoter/transgene activity in these cells.

Recent scRNA-seq analyses from Granneman and colleagues provide a cellular atlas of putative adipocyte precursor populations in adipose tissue ([@bib4]). Their analyses included all non-hematopoetic, non-endothelial cells of the isolated adipose stromal-vascular fraction. The strength of their approach is that it allows for one to capture both perivascular (PDGFRβ+) and non-perivascular precursor populations. Our approach will identify precursor populations that express *Pdgfrb/rtTA* at the time of the pulse labeling. *Pdgfrb* expression declines as cell undergo differentiation into adipocytes. This means that cells even further committed to the adipocyte lineage (i.e. no longer express *Pdgfrb*) may not be captured through our analysis. Moreover, putative stem cell populations not yet expressing *Pdgfrb* may also be present and not captured (e.g. Pref1^rtTA^ targeted cells \[[@bib21]\]). Nevertheless, it is notable that most of the adipocyte precursor populations represented in the study by Burl et al. were indeed captured in our analysis. One cannot rule out the existence of additional adipocyte progenitor populations in any particular adipose depot; however, the congruency of the two independent studies suggests the MuralChaser model can identify and target the major APC populations residing within visceral WAT of mice. Moreover, the selection of LY6C- PDGFRβ+ cells from gWAT using commercially available antibodies represents a refined and convenient strategy to isolate visceral adipocyte precursors from wild type mice or genetic mouse models of interest.

Single-cell transcriptomics has become very useful in revealing molecular heterogeneity amongst seemingly homogenous populations of cells. The challenge, however, is to determine whether molecularly distinct populations of cells represent distinct 'cell types,' or rather 'cell states' which are influenced by their local microenvironment. Here, we reveal molecular heterogeneity amongst PDGFRβ+ cells within visceral white adipose tissue and begin to define the functional differences between the identified subpopulations. Our functional analyses suggest that the properties of visceral FIPs are at least somewhat stable; FIPs are quite limited in adipogenic potential in vitro and upon transplantation. They do not readily activate *Pparg* expression under the conditions examined. The phenotype of visceral APCs may be less stable. Visceral APCs have the potential to adopt characteristics of FIPs. In vitro and in vivo following HFD, APCs can activate the expression of pro-inflammatory cytokines. A caveat to most of our functional studies is that the cells are studied outside their native microenvironment. Under some physiological conditions, it is certainly plausible that multiple PDGFRβ+ subpopulations give rise in vivo to adipocytes; such adipocytes might even possess unique functional characteristics. Our prior lineage-tracing studies using the MuralChaser model clearly established that adipocytes emerge from *Pdgfrb*-expressing cells; efforts to define the relative contribution of individual mural cell subpopulations will require more precise lineage-tracing approaches with more specific Cre drivers. Moreover, our current studies cannot exclude the possibility that even further heterogeneity exists amongst PDGFRβ+ cells or within the identified subpopulations. Deeper sequencing, refined analyses, and further functional studies may unveil even more heterogeneity than appreciated.

It is noteworthy that *Pdgfrb* is expressed in a subset of WAT associated mesothelial cells and that *Pdgfrb*-expressing mesothelial cells express *Pparg* and some level of *Zfp423*. As described above, several lines of evidence point to a lineage relationship between embryonic mesothelial cells, APCs, and perivascular stromal cells within the visceral compartment ([@bib7]; [@bib37]). PDGFRβ+ MLCs did not exhibit robust adipogenic potential under the culture conditions utilized here, despite their expression of *Pparg* isoform two and *Zfp423*. Additional signals may be needed in order to drive adipocyte differentiation from these cells. Alternatively, this subpopulation of mesothelial cells may represent developmental intermediates between mesothelial cells and perivascular progenitors. Further insight into the functional significance of these various stromal subpopulations, their developmental origins, and their cellular plasticity will require additional genetic tools to manipulate individual populations selectively in vivo. Nevertheless, the molecular profiles obtained for FIPs and APCs from visceral WAT, along with the strategies to isolate these cells, will facilitate the study of physiological visceral WAT remodeling in vivo. Ultimately, unraveling the cellular and molecular determinants of WAT expansion and remodeling may lead to strategies to improve adipose tissue function and defend against metabolic disease.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\      Designation                        Source or reference          Identifiers                                                              Additional information
  or resource                                                                                                                                                           
  ---------------------------- ---------------------------------- ---------------------------- ------------------------------------------------------------------------ ------------------------
  Antibody                     anti-guinea pig Alexa 647          Invitrogen                   RRID:[AB_141882](https://scicrunch.org/resolver/AB_141882)               1:200

  Antibody                     anti-chicken Alexa 488             Invitrogen                   RRID:[AB_142924](https://scicrunch.org/resolver/AB_142924)               1:200

  Antibody                     anti-GFP                           Abcam                        RRID:[AB_300798](https://scicrunch.org/resolver/AB_300798)               1:700

  Antibody                     anti-Perilipin                     Fitzgerald                   RRID:[AB_1288416](https://scicrunch.org/resolver/AB_1288416)             1:1500

  Antibody                     CD24-APC                           eBioscience                  RRID:[AB_10852841](https://scicrunch.org/resolver/AB_10852841)           1:400

  Antibody                     CD31-FITC                          Biolegend                    RRID:[AB_312900](https://scicrunch.org/resolver/AB_312900)               1:400

  Antibody                     CD31-PerCP/Cy5.5                   Biolegend                    RRID:[AB_10612742](https://scicrunch.org/resolver/AB_10612742)           1:400

  Antibody                     CD34-APC                           Biolegend                    RRID:[AB_10553895](https://scicrunch.org/resolver/AB_10553895)           1:400

  Antibody                     CD38-FITC                          Biolegend                    RRID:[AB_312926](https://scicrunch.org/resolver/AB_312926)               1:400

  Antibody                     CD45-FITC                          Biolegend                    RRID:[AB_312973](https://scicrunch.org/resolver/AB_312973)               1:400

  Antibody                     CD45-PerCP/Cy5.5                   Biolegend                    RRID:[AB_893344](https://scicrunch.org/resolver/AB_893344)               1:400

  Antibody                     CD9-APC                            eBioscience                  RRID:[AB_10669565](https://scicrunch.org/resolver/AB_10669565)           1:400

  Antibody                     CD9-FITC                           Biolegend                    RRID:[AB_1279321](https://scicrunch.org/resolver/AB_1279321)             1:400

  Antibody                     FC Block                           BD Biosciences               RRID:[AB_394657](https://scicrunch.org/resolver/AB_394657)               1:200

  Antibody                     LY6C-APC                           Biolegend                    RRID:[AB_1732076](https://scicrunch.org/resolver/AB_1732076)             1:400

  Antibody                     LY6C-BV421                         Biolegend                    RRID:[AB_2562178](https://scicrunch.org/resolver/AB_2562178)             1:400

  Antibody                     PDGFRα-APC                         Biolegend                    RRID:[AB_2043970](https://scicrunch.org/resolver/AB_2043970)             1:200

  Antibody                     PDGFRβ-APC                         Biolegend                    RRID:[AB_2268091](https://scicrunch.org/resolver/AB_2268091)             1:50

  Antibody                     PDGFRβ-PE                          Biolegend                    RRID:[AB_1953271](https://scicrunch.org/resolver/AB_1953271)             1:50

  Antibody                     SCA-1-APC                          Biolegend                    RRID:[AB_313348](https://scicrunch.org/resolver/AB_313348)               1:400

  Chemical compound, drug      Trypsin                            Corning                      25--052 Cl                                                               

  Chemical compound, drug      BrdU                               Sigma                        B5002                                                                    

  Chemical compound, drug      BSA                                Fisher Scientific            BP1605                                                                   

  Chemical compound, drug      Collagenase D                      Roche                        11088882001                                                              

  Chemical compound, drug      Dexamethosone                      Sigma                        D4902                                                                    

  Chemical compound, drug      DMEM with 1 g/L glucose,\          Corning                      10--014-CV                                                               
                               L-glutamine, and\                                                                                                                        
                               sodium pyruvate                                                                                                                          

  Chemical compound, drug      DMEM/F12 with GlutaMAX             Gibco                        10565--018                                                               

  Chemical compound, drug      FBS                                Sigma                        12303C                                                                   

  Chemical compound, drug      FGF basic                          R and D Systems              3139-FB-025/CF                                                           

  Chemical compound, drug      Gentamicin Reagent (50 mg/ml)      Gibco                        15750--060                                                               

  Chemical compound, drug      Harris Eosin Solution              Sigma                        HT110116                                                                 

  Chemical compound, drug      Harris Hematoxylin Solution        Sigma                        HHS16                                                                    

  Chemical compound, drug      HBSS                               Sigma                        H8264                                                                    

  Chemical compound, drug      Insulin                            Sigma                        I6634                                                                    

  Chemical compound, drug      Isobutylmethyxanthine              Sigma                        I7018                                                                    

  Chemical compound, drug      ITS Premix                         BD Bioscience                354352                                                                   

  Chemical compound, drug      L-ascorbic acid-2-2phosphate       Sigma                        A8960                                                                    

  Chemical compound, drug      Lipofectamine LTX                  Invitrogen                   15338100                                                                 

  Chemical compound, drug      Lipopolysaccharides from\          Sigma                        L3024                                                                    
                               Escherichia coli O111:B4                                                                                                                 

  Chemical compound, drug      Matrigel Growth Factor\            Corning                      354230                                                                   
                               Reduced Membrane Matrix                                                                                                                  

  Chemical compound, drug      MCDB201                            Sigma                        M6770                                                                    

  Chemical compound, drug      M-MLV RT                           Invitrogen                   28025013                                                                 

  Chemical compound, drug      Oil Red O                          Sigma                        O0625                                                                    

  Chemical compound, drug      PBS                                Sigma                        D8537                                                                    

  Chemical compound, drug      pCMV-VSV-G                         Addgene                      8454                                                                     

  Chemical compound, drug      Penicillin Streptomycin Solution   Corning                      30--001 Cl                                                               

  Chemical compound, drug      Polybrene                          Sigma                        TR-1003                                                                  

  Chemical compound, drug      psPAX2                             Addgene                      12260                                                                    

  Chemical compound, drug      Random Primers                     Invitrogen                   48190011                                                                 

  Chemical compound, drug      Recombinant Human TGFβ−1           R and D Systems              240-B-002                                                                

  Chemical compound, drug      Recombinant Murine TNFα            PeproTech                    315-01A                                                                  

  Chemical compound, drug      Red Blood Cell Lysing\             Sigma                        R7757                                                                    
                               Buffer Hybri-Max                                                                                                                         

  Chemical compound, drug      SYBR Green PCR Master Mix          Applied Biosystems           4309155                                                                  

  Chemical compound, drug      Trizol                             Invitrogen                   15596018                                                                 

  Commercial assay or kit      Chromium i7 Multiplex\             10X Genomics                 120262                                                                   
                               Kit, 96 rxns                                                                                                                             

  Commercial assay or kit      Chromium Single Cell 3\'\          10X Genomics                 120237                                                                   
                               Library and Gel Bead\                                                                                                                    
                               Kit v2, 16 rxns                                                                                                                          

  Commercial assay or kit      Chromium Single Cell A\            10X Genomics                 120236                                                                   
                               Chip Kit, 48 rxns                                                                                                                        

  Commercial assay or kit      Dynabeads MyOne Silane             Thermo Fisher Scientific     37002D                                                                   

  Commercial assay or kit      FITC BrdU Flow Kit                 BD Biosciences               559619                                                                   

  Commercial assay or kit      RNAqueous-Micro Total\             Invitrogen                   AM1931                                                                   
                               RNA Isolation Kit                                                                                                                        

  Commercial assay or kit      SPRIselect                         Beckman Coulter              B23317                                                                   

  Other                        100 µm cell strainer               Falcon                       352360                                                                   

  Other                        12-well plate                      Corning                      356500                                                                   

  Other                        40 µm cell strainer                Falcon                       352340                                                                   

  Other                        48-well plate                      Falcon                       353230                                                                   

  Other                        doxycyline-containing chow\        Bio-Serv                     S4107                                                                    
                               diet (600 mg/kg doxycycline)                                                                                                             

  Other                        high-fat diet (60% kcal% fat)      Research Diets               D12492i                                                                  

  Software, algorithm          Cell Ranger v2.1.0                 10X Genomics                 NA                                                                       

  Software, algorithm          FlowJo V10                         FlowJo                       RRID:[SCR_008520](https://scicrunch.org/resolver/SCR_008520)             

  Software, algorithm          Gene Set Enrichment\               Broad Institute              RRID:[SCR_003199](https://scicrunch.org/resolver/SCR_003199)             
                               Analysis v3.0                                                                                                                            

  Software, algorithm          Graphpad Prism 7                   Graphpad                     RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)             

  Software, algorithm          R Studio v3.3.2                    RStudio                      RRID:[SCR_000432](https://scicrunch.org/resolver/SCR_000432)             

  Software, algorithm          Readr v1.1.0                       NA                           NA                                                                       

  Software, algorithm          Seurat v2.1.0                      Satija Lab                   RRID:[SCR_016341](https://scicrunch.org/resolver/SCR_016341)             

  Strain, strain background\   C57BL/6                            Charles River Laboratories   RRID:[IMSR_CRL:27](https://scicrunch.org/resolver/IMSR_CRL:27)           
  (M. musculus, C57BL/6)                                                                                                                                                

  Strain, strain background\   *Pdgfrb*^rtTA^                     Jackson Laboratories         RRID:[IMSR_JAX:028570](https://scicrunch.org/resolver/IMSR_JAX:028570)   
  (M. musculus, C57BL/6)                                                                                                                                                

  Strain, strain background\   *Rosa26R*^mT/mG^                   Jackson Laboratories         RRID:[IMSR_JAX:007676](https://scicrunch.org/resolver/IMSR_JAX:007676)   
  (M. musculus, C57BL/6)                                                                                                                                                

  Strain, strain background\   *TRE-Cre*                          Jackson Laboratories         RRID:[IMSR_JAX:006234](https://scicrunch.org/resolver/IMSR_JAX:006234)   
  (M. musculus, C57BL/6)                                                                                                                                                

  Strain, strain background\   *Zfp423*^GFP^                      Other                        *Zfp423*^GFPB6^                                                          PMID: 26626462
  (M. musculus, C57BL/6)                                                                                                                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals and diets {#s4-1}
-----------------

All animal experimens were performed according to procedures approved by the UTSW Animal Care and Use Committee. MuralChaser mice were derived from breeding *Pdgfrb*^rtTA^ (JAX 028570), *TRE-Cre* (JAX 006234), and *Rosa26R*^mT/mG^ (JAX 007676) mice, as previously described ([@bib48]). Wildtype C57BL/6 mice mice were purchased from Charles River Laboratories and *Zfp423*^GFPB6^ mice were described previously ([@bib48]). Mice were maintained on a 12 hr light/dark cycle in a temperature-controlled environment (22°C) and given free access to food and water. Mice were fed a standard rodent chow diet, doxycyline-containing chow diet (600 mg/kg doxycycline, Bio-Serv, S4107), or high-fat diet (60% kcal% fat, Research Diets, D12492i). For all experiments involving MuralChaser mice, 6 weeks-old mice were fed doxycycline-containing chow for 9 days, and then standard chow for additional 5 days before analysis (doxcycyline washout). For the high fat diet feeding experiments, mice were placed on the high fat diet beginning at 8 weeks of age.

Histological analysis {#s4-2}
---------------------

Adipose tissues were harvested from perfused (4% paraformaldehyde) mice. Paraffin embedding and tissue sectioning was performed by the Molecular Pathology Core Facility at UTSW. Indirect immunofluorescence was performed as previously described ([@bib48]). Antibodies used for immunofluorescence include: anti-GFP 1:700 (Abcam ab13970), anti-perilipin 1:1500 (Fitzgerald 20R-PP004), anti-chicken Alexa 488 1:200 (Invitrogen), and anti-guinea pig Alexa 647 1:200 (Invitrogen). Hematoxylin and eosin staining was performed according to manufacturer's instructions.

Gene expression analysis by quantitative PCR {#s4-3}
--------------------------------------------

RNA was isolated from freshly sorted cells using RNAqueous-Micro Total RNA Isolation Kit (Thermo Fisher Scientific) or from cell cultures using Trizol, according to manufacturer's instructions. cDNA was synthesized using M-MLV Reverse Transcriptase (Invitrogen) and Random Primers (Invitrogen). Relative mRNA levels were determined by quantitative PCR using SYBR Green PCR Master Mix (Applied Biosystems). Values were normalized to Rps18 levels using the ΔΔ-Ct method. Unpaired Student\'s t-test was used to evaluate statistical significance. All primer sequences are listed within [Table 4](#table4){ref-type="table"}.

10.7554/eLife.39636.025

###### Sequences of qPCR primers used in this study.

  Gene                Forward 5\'−3\'            Reverse 5\'−3\'
  ------------------- -------------------------- --------------------------
  *Abcg1*             CAGCCTCTGGAGGGATTCTTT      ATCCCACGGCACTCTCACTTA
  *Adipoq*            AGATGGCACTCCTGGAGAGAA      TTCTCCAGGCTCTCCTTTCCT
  *Adipsin*           CTACATGGCTTCCGTGCAAGT      AGTCGTCATCCGTCACTCCAT
  *Agpat2*            CGAAGCTCTTCACCTCAGGAA      TCTGTAGAAAGGTGGCCCTCA
  *Agt*               GTTCTGGGCAAAACTCAGTGC      GAGGCTCTGCTGCTCATCATT
  *Car3*              CTTTGGAGAGGCTCTGAAGCA      ATCTGGAACTCGCCTTTCTCC
  *Ccl2*              CCACAACCACCTCAAGCACTTC     AAGGCATCACAGTCCGAGTCAC
  *Cd24*              CCTCCTCCTGTGGCTTTAGGTCTG   GGTGCTTGTGGTGAGTGAGAAACG
  *Cd34*              TGTGAAAAGGAGGAGGCTGAG      GTTTGCTGGGAAGTTCTGTGC
  *Cd36*              GAGTTGGCGAGAAAACCAGTG      GAGAATGCCTCCAAACACAGC
  *Cd38*              GCACCTTTGGAAGTGTGGAAG      CATGCGTTACTGGAAGCTCCT
  *Cebpa*             CAAGAACAGCAACGAGTACCG      GTCACTGGTCAACTCCAGCAC
  *Chst4*             CAGCAAACAGCATCTGTGGAG      CTTCGGAAAGATGTGGACAGG
  *Col1a1*            AGATGATGGGGAAGCTGGCAA      AAGCCTCGGTGTCCCTTCATT
  *Col2a1*            AGAACCTGGTACCCCTGGAAA      ACCACCAGCCTTCTCGTCATA
  *Col3a1*            ATTCTGCCACCCCGAACTCAA      ACAGTCATGGGGCTGGCATTT
  *Col5a1*            TGTCATGTTTGGCTCCCGGAT      AGTCATAGGCAGCTCGGTTGT
  *Cxcl10*            CTCAGGCTCGTCAGTTCTAAGT     CCCTTGGGAAGATGGTGGTTAA
  *Cxcl14*            TGGACGGGTCCAAGTGTAAGT      TCCTCGCAGTGTGGGTACTTT
  *Cxcl2*             ACTAGCTACATCCCACCCACAC     GCACACTCCTTCCATGAAAGCC
  *Dact2*             AGCCCCCTAAAGGAAGAAACC      GGTCCTTGGCCACAGTCATTA
  *Efhd1*             GGCCGCTCTAAGGTCTTCAAT      GTCAATAAAGCCGTCCCTTCC
  *F3*                AAGGATGTGACCTGGGCCTAT      AGTTGGTCTCCGTCTCCATGA
  *Fabp5*             GATGGGAAGATGATCGTGGAG      AACTCCTGTCCAGGATGACGA
  *Fn1*               GAGAGCACACCCGTTTTCATC      GGGTCCACATGATGGTGACTT
  *Glut4*             ATCTTGATGACCGTGGCTCTG      GCTGAAGAGCTCTGCCACAAT
  *Hspd1*             GCACGATCTATTGCCAAGGAG      TCTTCAGGGGTTGTCACAGGT
  *Il1b*              GCAACTGTTCCTGAACTCAACT     ATCTTTTGGGGTCCGTCAACT
  *Il6*               AAGCCAGAGTCCTTCAGAGAGA     ACTCCTTCTGTGACTCCAGCTT
  *Krt18*             GCTGCAGCTGGAGACAGAAAT      GTCAATCCAGAGCTGGCAATC
  *Krt8*              GAATGGCCACTGAAGTCCTTG      AGTTCCCTGCACTCTGCCATA
  *Lox*               TCGCTACACAGGACATCATGC      ATGTCCAAACACCAGGTACGG
  *Loxl2*             ACCCACGTCTGTATTCCATGC      CATCCAAGTCTTCAGCCATCC
  *Lrrn1*             CAACATGGGAGAGCTGGTTTC      GCACACTACGGAAAGCCAAAC
  *Ly6a*              ACACAGCCAGCACAGTGAAGA      CAGGGGGACATTCAGGATACA
  *Ly6c1*             ACTGTGCCTGCAACCTTGTCT      GGCCACAAGAAGAATGAGCAC
  *Mmd2*              ATCTGGGAGCTGATGACAGGA      AGTGGGTACCAGCACCAAATG
  *Nos2*              CCTCTGGTCTTGCAAGCTGAT      ACTCGTACTTGGGATGCTCCA
  *Nov*               GTTCCAAGAGCTGTGGAATGG      CTCTTGTTCACAAGGCCGAAC
  *Nr4a1*             TCTCTGGTTCCCTGGACGTTA      ACCGGGTTTAGATCGGTATGC
  *Nr4a1-1317*        TGCCTCCCCTACCAATCTTCT      TAACGTCCAGGGAACCAGAGA
  *Nr4a1-1468*        TCTCTGGTTCCCTGGACGTTA      ACCGGGTTTAGATCGGTATGC
  *Nr4a1-1877*        CGCATTGCTAGCTGTCTGAAAG     AATAGGTGGAGGGGGTACCA
  *Nr4a2*             ACACAGCGGGTCGGTTTACTA      ATGCGTAGTGGCCACGTAGTT
  *Nr4a3*             ACTTGCAGAGCCTGAACCTTG      TTGGTGCATAGCTCCTCCACT
  *Pde11a*            CGAGCTTGTCAGGAAAGGAGA      TTCAGCCACCTGTCTGGAGAT
  *Pdgfra*            ATCAGCTTGGCTCTTCCCTTC      TATAGCTTCCTGCTCCCGTCA
  *Pdgfrb*            AGGGGGTGATAGCTCACATCA      AGCCATAACACGGACAGCAAC
  *Pkhd11b*           CAGATTGGGACAGAAGCATCC      ACAGGAATAGGCAGACCGTGA
  *Plin1*             CAGTTCACAGCTGCCAATGAG      ATGGTGCCCTTCAGTTCAGAG
  *Pparg* isoform 1   TGAAAGAAGCGGTGAACCACT      TGGCATCTCTGTGTCAACCAT
  *Pparg* isoform 2   GCATGGTGCCTTCGCTGA         TGGCATCTCTGTGTCAACCATG
  *Rbp4*              TCTGTGGACGAGAAGGGTCAT      TGTCTGCACACACTTCCCAGT
  *Rps18*             CATGCAAACCCACGACAGTA       CCTCACGCAGCTTGTTGTCTA
  *Stmn4*             ACCTGAACTGGTGCGTCATCT      CTTGGGAGGGAGGCATTAAAC
  *Tgfb1*             TTTAGGAAGGACCTGGGTTGG      TGTTGGTTGTAGAGGGCAAGG
  *Tgfb2*             GGTGTTGTTCCACAGGGGTTA      CGGTCCTTCAGATCCTCCTTT
  *Tnfa*              GAAAGGGGATTATGGCTCAGG      TCACTGTCCCAGCATCTTGTG
  *Upk3b*             GCTTGGCCAACTTAACCTCCT      TGCTGCGTTCTCTGAAGTCTG
  *Zfp423*            CAGGCCCACAAGAAGAACAAG      GTATCCTCGCAGTAGTCGCACA

Isolation of adipose stromal vascular fraction (SVF) and flow cytometry {#s4-4}
-----------------------------------------------------------------------

Adipose tissue was minced with scissors in a 1.5 mL tube containing 200 μL of digestion buffer (1X HBSS, 1.5% BSA, and 1 mg/mL collagenase D) and then transferred to a 50 mL Falcon tube containing 10 mL digestion buffer. The mixture was incubated in a 37°C shaking water bath for 1 hr. The solution of digested tissue was passed through a 100 µm cell strainer, diluted to 30 mL with 2% FBS in PBS, and centrifuged at 500 x g for 5 min. The supernatant was aspirated and red blood cells in the SVF pellet were lysed by brief incubation in 1 mL RBC lysis buffer (Sigma). Next, the mixture was diluted to 10 mL with 2% FBS in PBS, passed through a 40 µm cell strainer, and then centrifuged at 500 x g for 5 min. The supernatant was aspirated, and cells were resuspended in blocking buffer (2% FBS/PBS containing anti-mouse CD16/CD32 Fc Block (1:200)). Primary antibodies were added to the cells in blocking buffer for 15 min at 4°C in the dark. After incubation, the cells were washed once with 2% FBS/PBS and then resuspended in 2% FBS/PBS for sorting. Cells were sorted for collection using a BD Biosciences FACSAria cytometer or analyzed using a BD Biosciences LSR II cytometer (UTSW Flow Cytometry Core Facility). Flow cytometry plots were generated with FlowJo (V10).

BrdU assays {#s4-5}
-----------

Eight week-old mice were administered 0.8 mg/mL BrdU in drinking water (replaced fresh every 2 days) and placed on chow or high fat diet for 1 week. At the end of the treatment period, adipose tissue SVF was isolated as described above and stained with the following antibodies: CD31, CD45, PDGFRβ, LY6C, and CD9. Anti-BrdU staining of fixed cells was then conducted using the BrdU Flow Kit (BD Biosciences 559619), according to the manufacturer's protocol.

Single-cell RNA-sequencing and analysis {#s4-6}
---------------------------------------

Six-week-old male MuralChaser mice were fed doxycycline-containing chow diet for 9 days, followed by standard chow diet for 5 days. Following the 5 day washout period, gonadal WAT was isolated and digested as described above. tdTomato- mGFP+ cells were collected by FACS. Single cell library preparation was performed using the 10X Genomics Single Cell 3' v2 according to the manufacturer's instructions.

After FACS isolation of gonadal WAT tdTomato- mGFP+ cells from MuralChaser mice, 10,000 cells were partitioned into droplets containing a barcoded bead, a single cell, and reverse transcription enzyme mix using the GemCode instrument. This was followed by cDNA amplification, fragmentation, end repair and A-tailing, adaptor ligation, and index PCR. Cleanup and size selection were performed using Dynabeads MyOne Silane beads (Thermo Fisher Scientific) and SPRIselect Reagent beads (Beckman Coulter). Libraries were sequenced on an Illumina NextSeq 500 High Output (400M) by the UT Southwestern McDermott Center Next Generation Sequencing Core. 75 paired-end reads were obtained using one flow cell with the following length input: 26 bp Read 1, 66 bp Read 2, 0 bp Index 1, and 0 bp Index 2.

Cell Ranger software (v2.1.0) was used to perform demultiplexing, aligning reads, filtering, clustering, and gene expression analyses, using default parameters. We recovered 1378 cells with a median UMI count of 10,879 per cell, a mean reads per cell of 277,212, and a median genes per cell of 3278. In order to ensure that our analysis was restricted to genetically marked *Pdgfrb*-expressing cells, we filtered the cells based on expression of *tdTomato* ([\<]{.ul}0) and *GFP* (\>0) to only include cells in the final analysis that were devoid of *tdTomato* mRNA and expressed *GFP* transcript. After this screening, we obtained a total of 1,045 cells for the analysis shown in [Figure 1](#fig1){ref-type="fig"}. The Cell Ranger data was imported into Loupe Cell Browser Software (v1.0.5) for t-distributed stochastic neighbor embedding (*tSNE*) based clustering, heatmap generation, and gene expression distribution plots. The Cell Ranger files were imported into R Studio (v3.3.2) and the Seurat (v2.1.0) and Readr (v1.1.0) packages were used to generate gene cluster text (GCT) and categorical class (CLS) files, using the clustering generated from Cell Ranger (*k*-means = 4 for the analysis in [Figure 1](#fig1){ref-type="fig"} and *k*-means = 3 for the analysis in [Figure 2](#fig2){ref-type="fig"}). The GCT and CLS files were input into Gene Set Enrichment Analysis (GSEA) (v3.0) using the Java GSEA implementation with default parameters. The single cell RNA-sequencing experiment was repeated using cells isolated from pooled gonadal WAT from five additional MuralChaser mice to validate the identification of APCs, FIPs, and MLCs ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The raw sequencing data from [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} has been deposited to Gene Expression Omnibus (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111588>).

In vitro adipocyte differentiation {#s4-7}
----------------------------------

For all cellular assays, 4--6 weeks-old C57BL/6 mice were utilized. PDGFRβ+ subpopulations were isolated from gonadal WAT SVF as described above. For spontaneous adipogenesis assays, sorted cells were plated in 48-well plates at a density of 4 × 10^4^ cells/well in growth media containing 2% FBS and ITS supplement \[60% pH7--7.4 low glucose DMEM, 40% pH 7.25 MCDB201 (Sigma M6770), 1% ITS premix (Insulin-Transferrin-Selenium) (BD Bioscience 354352), 0.1 mM L-ascorbic acid-2-2phosphate (Sigma A8960-5G), 10 ng/mL FGF basic (R and D Systems 3139-FB-025/CF), Pen/Strep, and gentamicin\] and incubated at 37°C in 10% CO~2~. Media was replaced every other day. For induced adipogenesis, confluent cultures of FIPs were treated with an adipogenesis induction cocktail (growth media supplemented with 5 mg/ml insulin, 1 μM dexamethasone, 0.5 mM isobutylmethyxanthine, ±1 μM rosiglitazone) for 48 hr. After 48 hr., the cells were maintained in growth media.

Oil red O staining {#s4-8}
------------------

Cells were fixed in 4% PFA for 15 min at room temperature and washed twice with water. Cells were incubated in Oil Red O working solution (2 g Oil red O in 60% isopropanol) for 10 min to stain accumulated lipids. Cells were then washed three times with water and bright field images were acquired using a document scanner or with a Keyence BZ-X710 Microscope.

Mesothelial cell isolation {#s4-9}
--------------------------

Adipose associated mesothelial cells were isolated as described previously ([@bib9]). Epididymal adipose depots were harvested from 6 weeks-old male MuralChaser mice treated with doxycyline as described above. Intact whole adipose depots were placed in 10 mL of PBS containing 0.25% trypsin for 20 min at 37°C with continuous end over end rotation. Next adipose tissues were removed, and remaining solution containing isolated cells was centrifuged at 600 x g for 5 min. The media was aspirated, and the cell pellet was resuspended in growth media (10% FBS in DMEM/F12 (Invitrogen)) and plated in a 12-well collagen-coated plate. The cells were incubated at 37°C in 10 CO~2~ and the media was replaced daily. Images were obtained using a Leica DMIL LED microscope and a Leica DFC3000g camera.

Cellular assays {#s4-10}
---------------

To assess in vitro proliferation, sorted cells (APCs and FIPs) were plated at a density of 5 x 10^3^ cells/well in a 48-well plate containing 2% FBS in ITS Media. Cell numbers were assessed in parallel wells every 2 days by cell counting with a hemocytometer. To study the impact of conditioned media on adipogenesis, media from equally confluent cultures of APCs, FIPs, and MLCs was harvested and placed onto APCs beginning 48 hr after culture in a 1:1 ratio with 2% FBS in ITS media. Cells were harvested at the indicated time points for RNA expression analysis. Images were obtained using a Leica DMIL LED microscope and a Leica DFC3000g camera.

Bone marrow derived macrophages (BMDMs) were derived from bone-marrow stem cells (BMSCs) isolated from the femurs and tibias of male mice, as previously described ([@bib41]). BMSCs were maintained in differentiation medium derived from L929 cells for 7 days to allow for macrophage differentiation. In parallel, adipose tissue SVF was isolated and PDGFRβ+ subpopulations were sorted as described above. Sorted cells (APCs, FIPs, and MLCs) were plated in a 48-well plate at 4 × 10^4^ cells/well in 2% FBS in ITS media. 48 hr later, the adipose-derived cells were treated with vehicle (PBS) or LPS (100 ng/ml) for 3 hr. Next the adipose-derived cells were washed with PBS and fresh media was added. 24 hr later, the conditioned media was harvested and placed on the BMDMs (at day 7) in a 1:1 ratio with 2% FBS in ITS media. After a 3 hr incubation, the BMDMs were harvested for RNA analysis.

For TGFβ treatments, sorted cells were plated in 48-well plates at 2 × 10^4^ cells/well in 2% FBS in ITS media. 24 hr later, vehicle (PBS) or 1 ng/mL recombinant TGFβ was added to the media for 3 days prior to harvest. The media was replaced daily under this period. For the LPS and TNFα treatments, cells were plated in 48-well plates at 4 × 10^4^ cells/well in 2% FBS in ITS media. 48 hr later, the cells were treated with vehicle (PBS), LPS (100 ng/ml), or TNFα (20 ng/ml). After 3 hr of treatment, cells were harvested for RNA isolation.

Cell transplantation assays {#s4-11}
---------------------------

80,000 cells (APCs and FIPs) collected by FACS were suspended in 100 µL transplantation media (50% Matrigel in PBS, supplemented with 2 ng/mL FGF) and injected subcutaneously into the remnant inguinal WAT region of 3 month old lipodystrophic mice (*Adiponectin*-Cre; *Pparg*^loxP/loxP^). Three weeks later, the remnant inguinal WAT depots were harvested for histology.

Retroviral production and transduction of primary cells {#s4-12}
-------------------------------------------------------

The pMSCV-Nr4a1, pMSCV-Nr4a2, and pMSCV-Nr4a3 plasmids were previously reported (kind gift from Dr. P. Tontonoz) ([@bib6]). Retroviral production and packaging in phoenix cells was performed as previously described ([@bib42]). Briefly, 10 µg of the pMSCV overexpression plasmids were co-transfected with 5 µg gag-pol and 5 µg VSV-g plasmids into phoenix packaging cells using Lipofectamine LTX (Thermo Fisher Scientific), according to the manufacturer's protocol. APCs and FIPs were transduced with diluted virus (1:10 ratio) in 2% FBS/ITS media containing 8 µg/ml polybrene (Sigma). Following 16 hr of incubation with indicated viruses, cells were returned to 2% FBS/ITS media and assayed for TNFα responsiveness as indicated.

Double-stranded DNA sequence encoding the shRNA targeting *Nr4a1* was selected from the Broad Institute public database (<https://portals.broadinstitute.org/gpp/public/>) and cloned into the AgeI/EcoRI sites of the pMKO-1 U6 retroviral vector. The pMKO-1 vector expressing shRNA targeting GFP was used as a negative control. The selected DNA sequences encoding the *Nr4a1* shRNAs used in the study are as follows: shNr4a1-1317 forward oligonucleotide,

5′-CCGGTGCCGGTGACGTGCAACAATTCTCGAGAATTGTTGCACGTCACCGGCATTTTTG-3′; shNr4a1-1317 reverse oligonucleotide,

5′-AATTCAAAAATGCCGGTGACGTGCAACAATTCTCGAGAATTGTTGCACGTCACCGGCA-3′. shNr4a1-1468 forward oligonucleotide,

5′-CCGGCGCCTGGCATACCGATCTAAACTCGAGTTTAGATCGGTATGCCAGGCGTTTTTG-3′; shNr4a1-1468 reverse oligonucleotide,

5′-AATTCAAAAACGCCTGGCATACCGATCTAAACTCGAGTTTAGATCGGTATGCCAGGCG-3′. shNr4a1-1877 forward oligonucleotide,

5′-CCGGCTATTGTGGACAAGATCTTTACTCGAGTAAAGATCTTGTCCACAATAGTTTTTG-3′; shNr4a1-1877 reverse oligonucleotide,

5′-AATTCAAAAACTATTGTGGACAAGATCTTTACTCGAGTAAAGATCTTGTCCACAATAG-3′.

Statistical analysis {#s4-13}
--------------------

All data were expressed as the mean +SEM. We used GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA, USA) to perform the statistical analyses. For comparisons between two independent groups, a Student's *t-*test was used and p\<0.05 was considered statistically significant. For in vitro studies, we estimated the approximate effect size based on independent preliminary studies. Studies designed to characterize an in vitro difference in gene expression were estimated to have a slightly larger effect size of 30% with assumed 15% standard deviation of group means. To detect this difference at a power of 80% and an alpha of 0.05, we predicted we would need four independent replicates per group. We estimated this effect size based on independent preliminary studies. Statistical information, including p values, samples sizes, and repetitions, for all datasets are provided in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.
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The following dataset was generated:

Gupta RKHepler C2018Single cell RNA-sequencing of visceral adipose tissue Pdgfrβ+ cells<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111588>Publicly available at the NCBI Gene Expression Omnibus (accession no. GSE111588)
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Decision letter

In the interests of transparency, eLife includes the editorial decision letter, peer reviews, and accompanying author responses.

\[**Editorial note:** This article has been through an editorial process in which the authors decide how to respond to the issues raised during peer review. The Reviewing Editor\'s assessment is that all the issues have been addressed.\]

Thank you for submitting your article \"Identification of functionally distinct fibro-inflammatory and adipogenic stromal subpopulations in visceral adipose tissue of adult mice\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Peter Tontonoz as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Marianne Bronner as the Senior Editor. The other two reviewers remain anonymous.

The Reviewing Editor has highlighted the concerns that require revision and/or responses, and we have included the separate reviews below for your consideration. If you have any questions, please do not hesitate to contact us.

Summary:

Gupta and colleagues combine single cell transcriptomics with FACS to define the heterogeneity of a population of PDGFRβ-positive cells that reside in the adipose tissue stromal vascular fraction and are enriched for adipogenic precursors. They identify distinct clusters of cells that are postulated to represent adipocyte precursors, committed preadipocytes, fibro-inflammatory progenitors, and mesothelial-like cells. They further show that the fibro-inflammatory progenitor FIP pool lacks adipogenic capacity, and that this may be due to production of a secreted factor.

Essential revisions:

The individual reviews are included for the authors consideration. We understand that major additional in vivo work is beyond the scope of a revision. We request that the authors give particular attention to the following issues in preparing their revision.

1\) It would be informative to include a comparison and discussion of the relationship between the cell populations described here and those identified in other recent scRNA-Seq papers on adipocyte precursors.

2\) Please discuss the implications of the findings for visceral fat expansion as mentioned by reviewers 1 and 3.

3\) Please consider whether it might be possible to use the new markers revealed by scSeq here to identify cell populations in tissue (e.g. by immunofluorescence) as suggested by reviewer \#3.

Separate reviews (please respond to each point):

*Reviewer \#1:*

Adipose tissue is remarkably heterogenous and various cell types in adipose contribute to its overall function. The authors had previously reported a population of PDGFRβ+ cells that give rise to white adipocytes in visceral fat. Using scRNA-Seq, the authors in this manuscript characterize various cell population within the PDGFRβ expressing cells. The manuscript reports FIP cell population that have highly compromised adipogenic potential and inhibits APCs adipogenic capacity in a paracrine-manner. The findings in the manuscript are interesting and the experiments are well-designed. Several questions that the authors might consider addressing are provided below.

Comments:

1\) Although likely beyond the scope of the present study, it will be interesting to test the in vivo differentiation potential of APCs, FIPs, and MLCs by implantation.

2\) Will the knockdown of NR4a members increase FIPs adipogenic potential?

3\) Since NR4a is expressed by different cell types and had been previously shown to affect adipogenesis. Will deleting some of the identified genes in the FIP population (Figure 1 or Figure 2G) rescue the non-adipogenic phenotype?

4\) Do the FIPs share some cellular and genetic identities with adipose CD142+/ABCG1+ SVF cells or vice-versa? These cells were also recently reported to be refractory to adipogenesis (PMID:29925944). Interestingly, CD142+cells were also shown to populate perivascular region in adipose.

5\) In Figure 6A, FIP population increases and APC population markedly decreases under high-fat diet. Visceral fat expands by both hypertrophy and hyperplasia and APCs could be responsible for healthy adipose expansion and accounts for the majority of de novo adipogenesis within PDGFRβ+ cells. Please explain this paradox.

6\) Will the conditioned media from FIPs also affect adipogenic potential of tdTomato expressing cells?

7\) In Figure 3, the authors should also test the proliferative capacity of the isolated cells.

*Reviewer \#2:*

The manuscript by Hepler et al. employed single-cell RNA sequencing and analyzed cellular heterogeneity in the stromal fraction of visceral adipose tissue. The bioinformatic analysis identified unique populations, including adipocyte precursor cells (APCs) and fibro-inflammatory progenitors (FIPs). The authors also established a robust sorting method to isolate APCs and FIPs by using their unique cell surface markers. Intriguingly, the authors found that FIPs acts on APCs to suppress their adipogenic potential via secretory factors, likely pro-inflammatory molecules. The authors further examined the extent to which a high-fat diet feeding affects the transcription profile of APCs and FIPs.

This is an outstanding paper that provides important insights into adipose progenitor heterogeneity and also useful information regarding the sorting method and the transcriptome data. Identification of Nr4a transcriptional factors suggests new regulators of FIPs. Overall, the data are convincing and the manuscript is well-written. Given the high significance and impact, this paper should be published in a timely manner. I have only minor comments that the authors wish to supplement in the paper.

1\) A recent paper by Granneman\'s group (Burl et al., 2018) reported scRNA-seq analysis and defined subpopulations of Lin- epididymal WAT. It would be interesting to cross the dataset and if any common genes/pathways are seen.

2\) TZDs are known to suppress inflammation and fibrosis pathways. Does TZD treatment inhibit pro-fibrosis and pro-inflammatory genes in FIPs?

3\. The authors wish to comment on any difference in APC and FIP populations between male and female mice.

Additional data files and statistical comments:

I think the study is rigorous.

*Reviewer \#3:*

The manuscript by Hepler et al. is part of a recent wave of studies using single cell RNA sequencing to define the adipocyte precursor cell population. Studies for many years prior suggest that adipocyte precursor pools are heterogeneous, but it has been difficult to define at the molecular level.

Here, the authors take advantage of recent advances in single cell transcriptomics combined with FACS to molecularly define the heterogeneity of a population of PDGFRβ-positive cells that they previously described, which reside in the adipose tissue stromal vascular fraction, and are highly enriched for adipogenic precursors. Base on gene expression signatures, they identify 4 distinct clusters of PDGFR-β expressing cells that in their model represent adipocyte precursors, committed preadipocytes, fibro-inflammatory progenitors, and mesothelial-like cells. They also find that the fibro-inflammatory progenitor pool (termed FIPs) lack adipogenic capacity, and have anti-adipogenic effects that may be linked to a secreted factor.

The study is timely, well done, interesting, and follows a logical course of investigation. The stated hypothesis is that PDGFRβ expressing cells in gonadal WAT are heterogeneous. This fairly safe hypothesis is supported by the data, and while these data are not overly surprising, they add important details to the molecular definition of what are currently considered to be \"APC\" pools. A particular strength of the study is the identification of unique markers that define each subpopulation of cells. The major weakness of the study is that it falls short of showing that these subpopulations, in particular the FIP population, are present and have anti-adipogenic potential in vivo. In summary, these data support the notion that current protocols used to isolate APCs result in highly heterogeneous populations, and will help in defining the hierarchy of adipocyte lineages, but await in vivo functional confirmation.

Major Points:

My major concern is that the clusters of cell types identified by sequencing and shown to have different functions in vitro have not been confirmed in vivo. The authors have nicely identified unique markers of the FIP population; could these markers be used to define the in vivo populations (without the caveats of isolating and purifying cells by FACS)? For example, can they distinctly localize the FIP, APC, and mesothelial-like cells? Could the authors show high in vivo expression of the NR4A receptors selectively in the FIP cells? Can the authors somehow confirm the role of NR4A in FIPs in vivo?

In a related point, the authors\' previous work suggests that all of the cells they sequenced here should express, or have previously expressed, *Pparg* (e.g. it was stated that PDGFRβ+ cells in gonadal WAT can be identified by *Pparg* expression). It is thus curious that non-adipogenic FIPs would express PPARg. It seems there could be an interesting biological reason for this (e.g. identity switching dependent on nutrient availability or other stimulus), but also potential technical caveats triggered by the isolation and purification strategy itself. This is why I think it is important to show that PDGFRβ+ (*pparg*+) FIP cells exist in the SVF in vivo (e.g. by immunofluorescence or similar strategy) and perform some type of in vivo loss-of-function analysis to demonstrate that these cells are (1) non-adipocyte forming and (2) anti-adipogenic to the APCs.

Other points:

Could the authors comment on the PDGFRβ-negative population of stromal vascular fraction cells that were selected against? Are there any adipogenic cells in this population and could the bias towards the PDGFRβ pool have caused the authors to miss important adipocyte progenitors?

A recent study by Deplancke, Wolfrum and colleagues in Nature similarly identified a population of anti-adipogenic cells they termed Aregs. In contrast to FIPs, Aregs appear to represent a small fraction of the APC pool. Are FIPs similar to Aregs? The same? Could the authors compare their gene signatures and comment on this?

Regarding the current studies\' rationale, it is stated (Introduction, second paragraph) that it has long been appreciated that individuals who preferentially accumulate WAT in subcutaneous regions are at lower risks for insulin resistance compared to those who accumulate visceral adiposity. It is stated in the third paragraph of the Introduction, that healthy WAT expansion occurs by hyperplasia. Yet, in the fourth paragraph of the Introduction, it is stated that (in mice) epididymal (visceral) WAT expands by hypertrophy and hyperplasia, but subcutaneous WAT almost exclusively by the stated unhealthy modality of hypertrophy. Thus, there is disconnect between subcutaneous being healthy but expanding by unhealthy means. Could the authors clarify this? It also raises the important question of whether subcutaneous WAT precursors also exhibit the same heterogeneity as the visceral WAT precursors described here by the authors. Could the authors show this and discuss their findings?

Using their gene expression data, could the authors show whether there is additional heterogeneity within the 4 clusters, or whether these populations represent fairly homogenous populations? This, is important towards the overall theme of \"heterogeneity\" in the APC pool and for helping readers understand how much the current strategy improves purity.

10.7554/eLife.39636.032

Author response

> Gupta and colleagues combine single cell transcriptomics with FACS to define the heterogeneity of a population of PDGFRβ-positive cells that reside in the adipose tissue stromal vascular fraction and are enriched for adipogenic precursors. They identify distinct clusters of cells that are postulated to represent adipocyte precursors, committed preadipocytes, fibro-inflammatory progenitors, and mesothelial-like cells. They further show that the fibro-inflammatory progenitor FIP pool lacks adipogenic capacity, and that this may be due to production of a secreted factor.

We thank the reviewers and editors for their careful consideration of our manuscript and for the very constructive feedback. As a result of the review/revision process, we feel the manuscript has improved. Further below, we provide a point-by-point response to individual critiques; however, the major changes can be summarized as follows:

\- Comparison of our results to the recently published results from other single-cell sequencing studies;

\- Additional functional analyses of APCs and FIPs, including in vivo transplantation studies and in vitro cell proliferation assays;

\- Analysis of perivascular cell heterogeneity in additional WAT depots; inclusion of female mice;

\- Further discussion of how FIPs may impact visceral adipose tissue remodeling and unresolved questions.

> Essential revisions:
>
> The individual reviews are included for the authors consideration. We understand that major additional in vivo work is beyond the scope of a revision. We request that the authors give particular attention to the following issues in preparing their revision.
>
> 1\) It would be informative to include a comparison and discussion of the relationship between the cell populations described here and those identified in other recent scRNA-Seq papers on adipocyte precursors.

We certainly agree that this is important. Deplanke/Wolfrum and colleagues defined an anti-adipogenic population of cells within inguinal WAT, termed Aregs (Schwalie et al., 2018). We now demonstrate that the visceral adipose FIPs described here are not enriched in the expression of markers used to define inguinal WAT Aregs. Despite some functional similarities (e.g. lack of adipogenic potential; anti-adipogenic), FIPs appear to be molecularly distinct from Aregs. These new data have been added to the new Figure 5.

Granneman and colleagues independently performed scRNA-seq of adipose SVF cells (Burl et al., 2018). The authors identified 2 prominent adipose stem cell (ASC) populations (termed ASC 1 and ASC 2) with the gonadal WAT depot. The identified populations were not isolated and explored functionally in their study; however, a comparison of the molecular profiles (now included here) strongly suggests that ASC 1 defined by the authors bears close resemblance to APC population defined in our study. Moreover, ASC 2 bears close resemblance to the FIPs discovered here. Importantly, the similarity in results between the two independent approaches suggest that the MuralChaser model captures a significantly large portion of the apparent visceral WAT adipocyte precursor pool, and that our new sorting strategy can be used to capture these cells. These new data are added to the Figure 3---figure supplement 1 of the revised manuscript.

> 2\) Please discuss the implications of the findings for visceral fat expansion as mentioned by reviewers 1 and 3.

The reviewers ask a number of great questions here. We appreciate the opportunity to discuss this further in the revised Discussion section. Our responses to the individual reviewer critiques are provided below.

> 3\) Please consider whether it might be possible to use the new markers revealed by scSeq here to identify cell populations in tissue (e.g. by immunofluorescence) as suggested by reviewer \#3.

We thank the reviewers for bringing up this important question. The identification of APCs and FIPs through the use of the MuralChaser mice essentially places these cells in the perivascular region of adipose tissue. As shown in the manuscript and in our prior publications (Hepler et al., 2017a; Hepler et al., 2017b; Shao et al., 2018; Vishvanath et al., 2016), mGFP expression in these reporter mice is confined to perivascular cells and to a few cells within the mesothelial layer of visceral WAT. Nevertheless, a simple tool to identify the specific subpopulations is needed for the field and is essential for understanding the spatial relationship between FIPs and APCs in vivo.

We have tried hard over the past year to find antibodies that 1) recognize proteins enriched in either FIPs or APCs, and 2) are suitable for immunohistochemistry (paraffin embedded sections). Specifically, we tested multiple commercial antibodies from Abcam, Cell Signaling, and other vendors, against LY6C, CD9, and other potential markers (AGT, DACT2, NR4A1, etc.). We do in fact observe staining patterns suggestive of heterogeneity within the PDGFRβ+ cells; however, we simply do not have confidence in any of these antibodies as the concentrations needed to obtain signal are quite high and we lack genetic controls to confirm their specificity. We are still actively working on developing these tools. We now discuss this issue in the revised Discussion section.

> Separate reviews (please respond to each point):

Reviewer \#1:

> Adipose tissue is remarkably heterogenous and various cell types in adipose contribute to its overall function. The authors had previously reported a population of PDGFRβ+ cells that give rise to white adipocytes in visceral fat. Using scRNA-Seq, the authors in this manuscript characterize various cell population within the PDGFRβ expressing cells. The manuscript reports FIP cell population that have highly compromised adipogenic potential and inhibits APCs adipogenic capacity in a paracrine-manner. The findings in the manuscript are interesting and the experiments are well-designed. Several questions that the authors might consider addressing are provided below.
>
> Comments:
>
> 1\) Although likely beyond the scope of the present study, it will be interesting to test the in vivo differentiation potential of APCs, FIPs, and MLCs by implantation.

This is great suggestion. We performed these studies by transplanting isolated APCs and FIPs into a recently described mouse model of complete lipodystrophy (Adiponectin-Cre; *Pparg^l^*^oxP/loxP^) (Wang et al., 2013). As expected in these types of assays, there was some degree of variability; however, in all four mice injected with APCs, adipocytes emerge and are readily detectable. On the other hand, transplanted FIPs did not give rise to adipocytes in any of the four mice tested. Even under these extreme lipodystrophic conditions, FIPs appear refractory to adipocyte differentiation. These new data have been added to Figure 3---figure supplement 3.

> 2\) Will the knockdown of NR4a members increase FIPs adipogenic potential?

Good question, especially in light of literature defining a role for NR4a members in suppressing adipogenesis (Chao et al., 2008). Knockdown of NR4a1 indeed led to an increase in the expression of *Pparg* in FIPs; however, this appeared to be insufficient in rendering cells more adipogenic, at least under the differentiation conditions utilized. This may be due to the fact that other NR4a family members serve in this capacity (Chao et al., 2008). We have opted not to include this in the manuscript as we are developing animal models to address this more thoroughly. We do, however, discuss this issue in the revised Discussion section.

> 3\) Since NR4a is expressed by different cell types and had been previously shown to affect adipogenesis. Will deleting some of the identified genes in the FIP population (Figure 1 or Figure 2G) rescue the non-adipogenic phenotype?

This is a great question. We have not yet performed a comprehensive functional screen of potential anti-adipogenic factors within FIPs (e.g. transcription factors) and/or secreted from FIPs (e.g. WNTs, TGFβ, etc.). This is the focus of ongoing/future studies in the lab.

> 4\) Do the FIPs share some cellular and genetic identities with adipose CD142+/ABCG1+ SVF cells or vice-versa? These cells were also recently reported to be refractory to adipogenesis (PMID:29925944). Interestingly, CD142+cells were also shown to populate perivascular region in adipose.

This is an important question. We now demonstrate that the visceral adipose FIPs described here are not enriched in the expression of markers used to define inguinal WAT Aregs. Despite some functional similarities (e.g. lack of adipogenic potential; anti-adipogenic), FIPs appear to be molecularly distinct from Aregs. These new data have been added to the new Figure 5.

*5) In Figure 6A, FIP population increases and APC population markedly decreases under high-fat diet. Visceral fat expands by both hypertrophy and hyperplasia and APCs could be responsible for healthy adipose expansion and accounts for the majority of de novo adipogenesis within PDGFR*β*+ cells. Please explain this paradox.*

This is a great question. "New" adipocytes originating from *Pdgfrb*-expressing cells first emerge within visceral WAT depots after 4 weeks of HFD feeding. The fact that the frequency of APCs decline by this time point may suggest that they have gone down the differentiation pathway (and no longer actively express *Pdgfrb*) and by this point are possibly depleted. With these new tools in hand, we are now revisiting the pattern of visceral fat expansion in obese mice, with a closer focus on the temporal and spatial events occurring following on the onset of HFD-feeding.

Nevertheless, the reviewer is correct that the increase in the frequency in FIPs is also somewhat puzzling. On one hand, the increase in this population correlates with the pathologic features of WAT expansion occurring following HFD feeding (inflammation/fibrosis). On the other hand, one may expect that the increased frequency of FIPs would completely blunt the differentiation of APCs. One possibility is that the anti-adipogenic activity of FIPs (rather than the frequency per se) is shut-off by local signals. Another possibility is that the spatial relationship between the two cell populations in vivo ultimately impacts how the cells interact. As now described in the revised Discussion section, further functional studies of these cells in vivo, using existing and perhaps new genetic tools, will be needed to further clarify the importance of these distinct mural cell phenotypes.

> 6\) Will the conditioned media from FIPs also affect adipogenic potential of tdTomato expressing cells?

We did not address this directly in our current study; however, we have observed that tdTomato expressing cells from gonadal WAT do not differentiate as readily as the mGFP+ cells in the model. This is not to say that other preadipocyte populations do not exist; the presence of immune cells, endothelial cells, and perhaps other tdTomato+ cell types in the SVF cultures may mask these cells, under the conditions we utilize.

> 7\) In Figure 3, the authors should also test the proliferative capacity of the isolated cells.

We thank the reviewer for this suggestion. Consistent with our observations in vivo, FIPs appear to proliferate much more rapidly than APCs upon plating in vitro. These new data are added to the new Figure 3---figure Supplement 1.

Reviewer \#2:

> The manuscript by Hepler et al. employed single-cell RNA sequencing and analyzed cellular heterogeneity in the stromal fraction of visceral adipose tissue. The bioinformatic analysis identified unique populations, including adipocyte precursor cells (APCs) and fibro-inflammatory progenitors (FIPs). The authors also established a robust sorting method to isolate APCs and FIPs by using their unique cell surface markers. Intriguingly, the authors found that FIPs acts on APCs to suppress their adipogenic potential via secretory factors, likely pro-inflammatory molecules. The authors further examined the extent to which a high-fat diet feeding affects the transcription profile of APCs and FIPs.
>
> This is an outstanding paper that provides important insights into adipose progenitor heterogeneity and also useful information regarding the sorting method and the transcriptome data. Identification of Nr4a transcriptional factors suggests new regulators of FIPs. Overall, the data are convincing and the manuscript is well-written. Given the high significance and impact, this paper should be published in a timely manner. I have only minor comments that the authors wish to supplement in the paper.

We thank the reviewer for his/her positive feedback and suggestions.

> 1\) A recent paper by Granneman\'s group (Burl et al., 2018) reported scRNA-seq analysis and defined subpopulations of Lin- epididymal WAT. It would be interesting to cross the dataset and if any common genes/pathways are seen.

This is a good suggestion. We discuss this issue above and repeat our response here for convenience:

Granneman and colleagues independently performed scRNA-seq of adipose SVF cells. The authors identified 2 prominent adipose stem cell (ASC) populations (termed ASC 1 and ASC 2) with the gonadal WAT depot. The identified populations were not isolated and explored functionally in their study; however, a comparison of the molecular profiles strongly suggests that ASC 1 defined by the authors bears close resemblance to APC population defined in our study. Moreover, ASC 2 bears close resemblance to the FIPs discovered here. Importantly, the similarity in results between the two independent approaches suggest that the MuralChaser model captures a significantly large portion of the apparent visceral WAT adipocyte precursor pool, and that our new sorting strategy can be used to capture these cells. These new data are added to the Figure 3---figure supplement 1 of the revised manuscript.

> 2\) TZDs are known to suppress inflammation and fibrosis pathways. Does TZD treatment inhibit pro-fibrosis and pro-inflammatory genes in FIPs?

This is a great question. In fact, we recently published that the beneficial effects of TZDs on gonadal WAT remodeling depend on PPARγ expression in *Pdgfrb*-expressing cells (Shao et al., 2018). Specifically, inducible deletion of PPARγ selectively in PDGFRβ+ cells blocks the ability of TZDs to promote adipocyte hyperplasia and suppress WAT inflammation. Whether the latter is due to an impact on FIPs is a great question. We are pursuing this question as part of a separate and extensive study (i.e. new mouse models) that focuses more broadly on the role of FIPs in regulating WAT inflammation.

> 3\) The authors wish to comment on any difference in APC and FIP populations between male and female mice.

This is an important point. The sorting strategy that we employ to isolate FIPs and APCs from visceral WAT can be used in both female and male mice. We added this new data to the new Figure 4---figure supplement 1.

> Additional data files and statistical comments:
>
> I think the study is rigorous.

Reviewer \#3:

> \[...\] The study is timely, well done, interesting, and follows a logical course of investigation. The stated hypothesis is that PDGFRβ expressing cells in gonadal WAT are heterogeneous. This fairly safe hypothesis is supported by the data, and while these data are not overly surprising, they add important details to the molecular definition of what are currently considered to be \"APC\" pools. A particular strength of the study is the identification of unique markers that define each subpopulation of cells. The major weakness of the study is that it falls short of showing that these subpopulations, in particular the FIP population, are present and have anti-adipogenic potential in vivo. In summary, these data support the notion that current protocols used to isolate APCs result in highly heterogeneous populations, and will help in defining the hierarchy of adipocyte lineages, but await in vivo functional confirmation.
>
> Major Points:
>
> My major concern is that the clusters of cell types identified by sequencing and shown to have different functions in vitro have not been confirmed in vivo. The authors have nicely identified unique markers of the FIP population; could these markers be used to define the in vivo populations (without the caveats of isolating and purifying cells by FACS)? For example, can they distinctly localize the FIP, APC, and mesothelial-like cells? Could the authors show high in vivo expression of the NR4A receptors selectively in the FIP cells? Can the authors somehow confirm the role of NR4A in FIPs in vivo?

This is a great point, and certainly a question that arises from all single cell sequencing studies. As noted above, we have made several attempts to localize these cell populations using commercially available antibodies recognizing FIPs and/or APC-selective proteins. We observe heterogeneous expression patterns within PDGFRβ+ cells; however, we are not yet confident enough in the specificity of the antibodies to suggest their use by the field.

A number of lines of evidence (independent of cell fractionation/FACs) suggest that mural cell heterogeneity exists in vivo. In fact, what motivated this study is the initial observation made from *Zfp423*^GFP^ reporter mice (Gupta et al., 2012; Vishvanath et al., 2016). Through the use of immunohistochemistry, we found that GFP expression in the adipose tissue of these animals can be found in a *subset* of perivascular cells. This is in line with earlier work from Graff and colleagues indicating that a subset of mural cells express *Pparg* (Tang et al., 2008).

*In a related point, the authors\' previous work suggests that all of the cells they sequenced here should express, or have previously expressed, Pparg (e.g. it was stated that PDGFRβ+ cells in gonadal WAT can be identified by Pparg expression). It is thus curious that non-adipogenic FIPs would express PPARg. It seems there could be an interesting biological reason for this (e.g. identity switching dependent on nutrient availability or other stimulus), but also potential technical caveats triggered by the isolation and purification strategy itself. This is why I think it is important to show that PDGFRβ+ (pparg+) FIP cells exist in the SVF in vivo (e.g. by immunofluorescence or similar strategy) and perform some type of in* vivo *loss-of-function analysis to demonstrate that these cells are (1) non-adipocyte forming and (2) anti-adipogenic to the APCs.*

This is an important point and we thank the reviewer for the opportunity to clarify. Our work, along with the work of others (primarily Graff and colleagues), demonstrate that PDGFRβ+ adipocyte precursors (i.e. the subpopulation of PDGFRβ+ cells with adipogenic potential) are enriched in *Pparg* and *Zfp423* expression. The reviewer is correct that FIPs express *Pparg* and *Zfp423*; however, the levels appear quantitatively lower in FIPs vs. APCs.

Regarding function, we have now performed transplantation assays of FIPs/APCs into lipodystrophic mice. As noted above, in all four mice injected with APCs, adipocytes emerge and are readily detectable. On the other hand, transplanted FIPs did not give rise to adipocytes in any of the four mice tested. Even under these extreme lipodystrophic conditions, FIPs appear refractory to adipocyte differentiation. These new data have been added to Figure 3---figure supplement 3.

We completely agree with the sentiment of the reviewer that the new populations described here, along with other recently identified populations from other groups, need to be explored further in vivo. We have a number of on-going animal studies that involve genetic manipulation of inflammatory and fibrogenic signaling cascades in PDGFRβ+ cells. We expect that these studies, when completed, will shed insight into the importance of these various mural cell phenotypes in adipose tissue remodeling.

> Other points:
>
> Could the authors comment on the PDGFRβ-negative population of stromal vascular fraction cells that were selected against? Are there any adipogenic cells in this population and could the bias towards the PDGFRβ pool have caused the authors to miss important adipocyte progenitors?

This is a great question. We have not explored the PDGFRβ- pool in any great depth. As such, we certainly cannot rule out that other precursors populations exist. In fact, our approach will only identify precursor populations that express *Pdgfrb/rtTA* at the time of the pulse labeling. *Pdgfrb* expression declines as cell undergo differentiation into adipocytes. This means that cells even further committed to the adipocyte lineage (i.e. no longer express *Pdgfrb*) would not be captured through our analysis. Moreover, putative stem cell populations not yet expressing *Pdgfrb* may also be present and not captured. All that being said, it is notable that our approach captured most, if not all, the precursor populations recently identified in the study by Granneman and colleagues. Their group performed single cell sequencing of the SVF from gonadal WAT, allowing them to capture (in principle) both PDGFRβ+ and PDGFRβ- precursors. As we now highlight in the revised manuscript, our analysis appears to capture the adipocyte precursor populations defined in their study. This does not exclude any possibility that additional populations exist; however, the similarity in results between the two independent approaches suggest that the MuralChaser model captures a significantly large portion of the apparent visceral WAT adipocyte precursor pool, and that our new sorting strategy can be used to capture these cells. We now discuss this more thoroughly in the revised Discussion section.

> A recent study by Deplancke, Wolfrum and colleagues in Nature similarly identified a population of anti-adipogenic cells they termed Aregs. In contrast to FIPs, Aregs appear to represent a small fraction of the APC pool. Are FIPs similar to Aregs? The same? Could the authors compare their gene signatures and comment on this?

As noted above, we certainly agree that this is important. Deplanke/Wolfrum and colleagues defined an anti-adipogenic population of cells within inguinal WAT, termed Aregs. We now demonstrate that the visceral adipose FIPs described here are not enriched in the expression of markers used to define inguinal WAT Aregs. Despite some functional similarities (e.g. lack of adipogenic potential; anti-adipogenic), Visceral WAT FIPs appear to be at least somewhat distinct from the inguinal WAT Aregs described. These new data have been added to Figure 5.

> Regarding the current studies\' rationale, it is stated (Introduction, second paragraph) that it has long been appreciated that individuals who preferentially accumulate WAT in subcutaneous regions are at lower risks for insulin resistance compared to those who accumulate visceral adiposity. It is stated in the third paragraph of the Introduction, that healthy WAT expansion occurs by hyperplasia. Yet, in the fourth paragraph of the Introduction, it is stated that (in mice) epididymal (visceral) WAT expands by hypertrophy and hyperplasia, but subcutaneous WAT almost exclusively by the stated unhealthy modality of hypertrophy. Thus, there is disconnect between subcutaneous being healthy but expanding by unhealthy means. Could the authors clarify this?

This is a good point, and we appreciate the opportunity to discuss this further here. Indeed, in male mice, the subcutaneous inguinal WAT depot expands almost exclusively by adipocyte hypertrophy. It should be noted that all of our studies, and almost all related studies, have been done with C57BL/6 mice. These animals are often utilized in our field because it is a model of pathologic diet-induced obesity. The inability of the subcutaneous WAT depot to expand in a healthy manner may contribute to the overall systemic phenotype of diet-induced obese C57BL/6 mice. In fact, engineered animal models exhibiting hyperplastic subcutaneous adipose expansion in obesity (examples: Adiponectin transgenic, mitoNeet transgenic, Glut4 transgenic) maintain insulin sensitivity despite becoming obese. What is certainly puzzling is that PDGFRβ+ cells isolated from this depot are highly adipogenic in vitro (as shown here), but are not activated in vivo to undergo adipogenesis, even when a *Pparg* transgene is expressed (Shao et al., 2018). As such, there appear to strong suppressive signals in the tissue microenvironment that restrain adipogenesis. Such signals may emanate from the recently identified Aregs, or from other cell types.

As the reviewer correctly points out, it is then somewhat surprising that visceral WAT depot expands by both cell hypertrophy and cellular hyperplasia. It is in our view that the level of de novo adipogenesis naturally occurring in this depot following the onset of HFD is beneficial, but insufficient to protect from pathological WAT expansion. This view is based on our recently published models in which allow for inducible expression or deletion of *Pparg* in PDGFRβ+ cells (Shao et al., 2018). Loss of *Pparg* in PDGFRβ+ cells leads to a loss of de novo adipogenesis from PDGFRβ+ cells in the visceral WAT depot of diet-induced obese mice; this exacerbates the pathologic remodeling of this depot (i.e. increased inflammation and fibrosis). However, driving further de novo adipogenesis from PDGFRβ+ cells through transgenic *Pparg* expression leads to a healthy expansion of visceral WAT (lower inflammation and small adipocytes).

This leads to the question raised by reviewer 1: Why don't the FIPs block de novo adipogenesis from the mural cell lineage in this depot? As noted above, it is possible that the anti-adipogenic activity of these cells is somewhat shut-off in the setting of nutrient excess, or turned on during later HFD feeding timepoints. In order to address this, we first need to identify the putative anti-adipogenic factor. Importantly, and as noted in the manuscript, further in vivo studies of FIPs and APCs will be needed in order to clarify their exact roles in WAT remodeling in vivo. We now address this issue directly in the revised Discussion.

> It also raises the important question of whether subcutaneous WAT precursors also exhibit the same heterogeneity as the visceral WAT precursors described here by the authors. Could the authors show this and discuss their findings?

Great point. Transcriptional programs of white adipocyte precursors are depot- dependent. The question raised by the reviewer here motivated us to ask whether similar functional heterogeneity exists amongst PDGFRβ+ cells within various WAT depots, and whether functionally distinct subpopulations could be selected for using the same FACS strategy described above. Indeed, the same three populations can be observed within the mesenteric and retroperitoneal depots of adult male mice, with LY6C- CD9- PDGFRβ+ cells representing the highly adipogenic subpopulation (new Figure 4A-H).

We also examined LY6C expression within PDGFRβ+ SVF cells obtained from the inguinal and anterior subcutaneous WAT depots. We previously demonstrated that the total pool of PDGFRβ+ cells from inguinal WAT is very highly adipogenic in vitro; however, remarkably, all PDGFRβ+ cells within the inguinal and anterior subcutaneous WAT depots expressed LY6C (new Figure 4I). These data suggest that if heterogeneity exists amongst PDGFRβ+ cells in these subcutaneous depots, they could not be discriminated on the basis of LY6C expression. Therefore, functionally distinct stromal populations from visceral, but not subcutaneous, WAT depots can be revealed on the basis of LY6C and CD9 expression.

On-going single cell sequencing studies in our lab are examining whether cell populations representing APCs and FIPs exist within subcutaneous WAT depots and brown adipose tissue depots, perhaps bearing distinct markers.

> Using their gene expression data, could the authors show whether there is additional heterogeneity within the 4 clusters, or whether these populations represent fairly homogenous populations? This, is important towards the overall theme of \"heterogeneity\" in the APC pool and for helping readers understand how much the current strategy improves purity.

We agree that this is an important question. Through further Cell Ranger analysis of APCs and FIPs, we did not see any clear and obvious subdivision of the two populations. This does not mean that APCs/FIPs are not and/or cannot be heterogeneous under any circumstance (e.g. in obesity). We are interested in further evaluating heterogeneity of potential subpopulations of FIPs and APCs in future studies, through 1) single cell-derived clonal analyses in vitro, and 2) additional scRNA-seq analyses (re-sequencing) of purified FIPs and APCs. In the revised Discussion section we further emphasize the potential importance of further analyses going forward.

[^1]: These authors contributed equally to this work.
